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Summary of findings {#CD010705-sec1-0001}
===================

Summary of findings 1MTBDR*sl* for FQ resistance, direct testing on smear‐positive specimens**Participants**: patients with rifampicin‐resistant or MDR‐TB\
**Prior testing:** patients who received MTBDR*sl* testing may have first received smear microscopy, Xpert® MTB/RIF or other nucleic acid amplification test, and culture to diagnose TB and Xpert® MTB/RIF, MTBDR*plus* version 2.0 or an alternative line‐probe assay to detect first‐line drug resistance\
**Role:** The role of MTBDR*sl* would be as the initial test, replacing culture‐based drug susceptibility testing, for detecting second‐line drug resistance\
**Settings:** intermediate or central level laboratories\
**Index (new) test:** MTBDR*sl* version 1.0.\* The test was performed by direct testing on smear‐positive specimens\
**Reference standard:** culture‐based drug susceptibility testing\
**Studies**: mainly cross‐sectional studies\
**Limitations**: most included studies did not consistently use the World Health Organization (WHO)‐recommended concentrations for drugs in the culture‐based reference standard\
**Pooled sensitivity (95% CI)**: 86.2% (74.6% to 93.0%) **Pooled specificity (95% CI)**: 98.6% (96.9% to 99.4%)**Test resultNumber of results per 1000 patients tested (95% CI)Number of participants (studies)Quality of the evidence (GRADE)Prevalence of 5%Prevalence of 10%Prevalence of 15%True positives** (patients correctly diagnosed with FQ resistance)43 (37 to 47)86 (75 to 93)129 (112 to 140)519 (9)⊕⊕⊕⊝^1,2,3,4^\
moderate**False negatives** (patients incorrectly classified as not having FQ resistance)7 (3 to 13)14 (7 to 25)21 (10 to 38)**True negatives** (patients correctly classified as not having FQ resistance)937 (921 to 944)887 (872 to 895)838 (824 to 845)1252 (9)⊕⊕⊕⊕^1,2,3^\
high**False positives** (patients incorrectly classified as having FQ resistance)13 (6 to 29)13 (5 to 28)12 (5 to 26)[^2]

Summary of findings 2MTBDR*sl* for SLID resistance, direct testing on smear‐positive specimens**Participants**: patients with rifampicin‐resistant or MDR‐TB\
**Prior testing:** patients who received MTBDR*sl* testing may have first received smear microscopy, Xpert® MTB/RIF or other nucleic acid amplification test, and culture to diagnose TB and Xpert® MTB/RIF, MTBDR*plus* version 2.0 or an alternative line‐probe assay to detect first‐line drug resistance\
**Role:** The role of MTBDR*sl* would be as the initial test, replacing culture‐based drug susceptibility testing, for detecting second‐line drug resistance\
**Settings:** intermediate or central level laboratories\
**Index (new) test:** MTBDR*sl* version 1.0.\* The test was performed by direct testing on smear‐positive specimens\
**Reference standard:** culture‐based drug susceptibility testing\
**Studies**: cross‐sectional studies\
**Limitations**: most included studies did not consistently use the World Health Organization (WHO)‐recommended concentrations for drugs in the culture‐based reference standard\
**Pooled sensitivity (95% CI)**: 87.0% (38.1% to 98.6%) **Pooled specificity (95% CI)**: 99.5% (93.6% to 100.0%)**Test resultNumber of results per 1000 patients tested (95% CI)Number of participants (studies)Quality of the evidence (GRADE)Prevalence of 5%Prevalence of 10%Prevalence of 15%True positives** (patients correctly diagnosed with SLID resistance)44 (19 to 49)87 (38 to 99)131 (57 to 148)348 (8)⊕⊕⊝⊝^1,2,3,4^\
low**False negatives** (patients incorrectly classified as not having SLID resistance)6 (1 to 31)13 (1 to 62)19 (2 to 93)**True negatives** (patients correctly classified as not having SLID resistance)945 (889 to 950)896 (842 to 900)846 (796 to 850)8 (1291)⊕⊕⊕⊝^1,2^\
moderate**False positives** (patients incorrectly classified as having SLID resistance)5 (0 to 61)4 (0 to 58)4 (0 to 54)[^3]

Summary of findings 3MTBDR*sl* for XDR‐TB, direct testing on smear‐positive specimens**Participants**: patients with rifampicin‐resistant or MDR‐TB\
**Prior testing:** patients who received MTBDR*sl* testing may have first received smear microscopy, Xpert® MTB/RIF or other nucleic acid amplification test, and culture to diagnose TB and Xpert® MTB/RIF, MTBDR*plus* version 2.0 or an alternative line‐probe assay to detect first‐line drug resistance\
**Role:** The role of MTBDR*sl* would be as the initial test, replacing culture‐based drug susceptibility testing, for detecting second‐line drug resistance\
**Settings:** intermediate or central level laboratories\
**Index (new) test:** MTBDR*sl* version 1.0.\* The test was performed by direct testing on smear‐positive specimens\
**Reference standard:** culture‐based drug susceptibility testing\
**Studies**: cross‐sectional studies\
**Limitations**: most included studies did not consistently use the World Health Organization (WHO)‐recommended concentrations for drugs in the culture‐based reference standard\
**Pooled sensitivity (95% CI)**: 69.4% (38.8% to 89.0%) **Pooled specificity (95% CI)**: 99.4% (95.0% to 99.3%)**Test resultNumber of results per 1000 patients tested (95% CI)Number of participants (studies)Quality of the evidence (GRADE)Prevalence of 1%Prevalence of 5%Prevalence of 10%True positives** (patients correctly diagnosed with XDR‐TB)7 (4 to 9)35 (19 to 45)69 (39 to 89)143 (6)⊕⊕⊝⊝^1,2,3,4^\
low**False negatives** (patients incorrectly classified as not having XDR‐TB)3 (1 to 6)15 (5 to 31)31 (11 to 61)**True negatives** (patients correctly classified as not having XDR‐TB)980 (941 to 983)941 (903 to 943)891 (855 to 894)1277 (6)⊕⊕⊕⊝^1,2^\
moderate**False positives** (patients incorrectly classified as having XDR‐TB)10 (7 to 49)9 (7 to 47)9 (6 to 45)[^4]

Background {#CD010705-sec1-0002}
==========

Tuberculosis (TB) is an infectious airborne disease caused by *Mycobacterium tuberculosis* bacteria. In 2014, an estimated 9.6 million people developed TB and 1.5 million people died from TB; 1.1 million among human immunodeficiency virus (HIV)‐negative people and 0.4 million among HIV‐positive people ([@CD010705-bbs2-0095]). Although the number of TB deaths has dropped by nearly half since 1990, TB is now the most common cause of death from an infectious disease in adults, surpassing HIV/acquired immune deficiency syndrome (AIDS), which claimed 1.2 million lives. TB is a preventable and treatable disease. The World Health Organization (WHO) estimated that, since 2000, 43 million lives have been saved through effective diagnosis and treatment ([@CD010705-bbs2-0095]).

TB predominantly affects the lungs (pulmonary TB) but can affect other parts of the body, such as the brain or the spine. Active TB disease is confirmed by the presence of TB bacilli grown in culture. The symptoms of pulmonary TB include a persistent cough (for at least two weeks), fever, night sweats, weight loss, chills, haemoptysis, and fatigue. TB that is drug sensitive (also referred to as drug‐susceptible TB) is the most common type of TB and may be effectively treated with a standardized regimen of first‐line anti‐TB drugs ([@CD010705-bbs2-0095]). However, TB bacilli may become drug resistant, meaning that first‐line anti‐TB drugs can no longer kill the bacilli. Drug resistance usually develops because of inappropriate or incorrect use of first‐line drugs, but new cases are increasingly caused by person‐to‐person transmission ([@CD010705-bbs2-0087]; [@CD010705-bbs2-0098]).

The emergence of drug‐resistant TB threatens to destabilize global TB control. There are two standardized definitions of drug‐resistant TB: multidrug‐resistant TB (MDR‐TB) and extensively drug‐resistant TB (XDR‐TB). MDR‐TB is caused by *M. tuberculosis* which, when tested microbiologically in the laboratory, is resistant to rifampicin and isoniazid. These drugs are two of the most effective and widely‐used anti‐TB drugs that form part of the standardized first‐line regimen for drug‐susceptible TB. Patients with MDR‐TB are commonly treated with drugs belonging to the fluoroquinolone (FQ) and second‐line injectable drug (SLID) anti‐TB drug classes. The FQ drugs include ofloxacin, levofloxacin, moxifloxacin, and gatifloxacin and the SLIDs include amikacin and kanamycin (two aminoglycoside drugs) and capreomycin (a cyclic peptide drug). XDR‐TB is caused by *M. tuberculosis* resistant to isoniazid, rifampicin, plus any FQ and at least one of the three SLIDs. Hence, patients with XDR‐TB are resistant to both first‐line and second‐line drugs.

Therapy for drug‐resistant TB requires treatment for more than 12 months and is toxic and expensive. A systematic review estimated only 62% (95% confidence interval (CI) 58% to 67%) of patients initiated on treatment for MDR‐TB were successfully treated (defined as cured or completed treatment, [@CD010705-bbs2-0077]). Around 10% of MDR‐TB patients have XDR‐TB, but this may be as high as 30% in parts of Eastern Europe ([@CD010705-bbs2-0095]). XDR‐TB treatment success rates are poor (26%), with high five‐year mortality (73%) in HIV‐endemic settings ([@CD010705-bbs2-0078]; [@CD010705-bbs2-0095]). In South Africa in 2011, the treatment of approximately 8000 cases of drug‐resistant TB, which comprised only 2.2% of the total TB burden, consumed 32% of the country\'s annual national TB budget of USD 218 million ([@CD010705-bbs2-0079]).

Improvements in the diagnosis of drug‐resistant TB are also important for reducing transmission. In South Africa, 80% of MDR‐TB is thought to be spread from person‐to‐person ([@CD010705-bbs2-0087]), and the same is likely true of MDR‐TB and XDR‐TB in China ([@CD010705-bbs2-0098]). Modelling studies have shown that, through the improvement of capacity to rapidly diagnose drug‐resistant TB, patient cure rates can be improved through the earlier initiation of appropriate and effective TB treatment ([@CD010705-bbs2-0061]; [@CD010705-bbs2-0062]; [@CD010705-bbs2-0066]). Importantly, this can reduce infectiousness within one to two weeks ([@CD010705-bbs2-0075]). However, the exact \'infectiousness period\' for drug‐resistant TB remains unclear. There is thus an urgent need for rapid tests that allow the early detection of drug resistance and the selection of appropriate drugs.

The use of conventional phenotypic culture‐based drug susceptibility testing (DST) for detection of drug‐resistant TB relies on the growth of TB bacteria and is therefore associated with considerable time delays (two to six months). These delays are exacerbated by the technical and infrastructure requirements of testing, the lack of standard methods for certain drugs and contamination (which cause unclear results that require repeating) ([@CD010705-bbs2-0082]), as well as patient‐associated difficulties, such as loss to follow‐up. Once a diagnosis of MDR‐TB has been established, second‐line DST is typically used to diagnose second‐line drug resistance. In 2015, 300,000 (of the estimated 450,000 cases) MDR‐TB cases were reported, yet only 24% received second‐line DST ([@CD010705-bbs2-0095]).

Molecular tests for detecting drug resistance such as the Genotype® MTBDR*sl* assay (henceforth called MTBDR*sl*) have shown promise for the diagnosis of drug‐resistant TB. These tests are rapid (around five hours), and genotypic, as they detect the presence of mutations associated with drug resistance. MTBDR*sl* belongs to a category of molecular genetic tests called line probe assays. MTBDR*sl* version 1.0 was the first commercial line probe assay for detection of resistance to second‐line TB drugs and, since the beginning of 2016, is no longer available. MTBDR*sl* version 2.0 was released in 2015. MTBDR*sl* version 2.0 detects the mutations associated with FQ and SLID resistance detected by MTBDR*sl* version 1.0, as well as additional mutations (described below). We have included a glossary of genetic terms in [Appendix 1](#CD010705-sec2-0015){ref-type="app"}. The draft of this updated Cochrane review informed the WHO Guideline Development Group that met February to March 2016 to make recommendations about the use of this test. The WHO policy guidance, \"The use of molecular line probe assays for the detection of resistance to second‐line anti‐tuberculosis drugs", was published in May 2016 ([@CD010705-bbs2-0096]).

Target condition being diagnosed {#CD010705-sec2-0001}
--------------------------------

We considered the following target conditions.

Fluoroquinolone (FQ) resistance.Second‐line injectable drug (SLID) resistance.XDR‐TB.

Index test(s) {#CD010705-sec2-0002}
-------------

The index test is MTBDR*sl* versions 1.0 and 2.0 ([@CD010705-bbs2-0072]; [Table 5](#CD010705-tbl-0005){ref-type="table"}). MTBDR*sl* detects specific mutations associated with resistance to the FQs (including ofloxacin, moxifloxacin, levofloxacin, and gatifloxacin) and SLIDs (including kanamycin, amikacin, and capreomycin) in *M. tuberculosis* complex species. Version 1.0 detects mutations in the *gyrA* quinolone resistance‐determining region (codons 88, 90, 91, 94) and *rrs* (codons 1401, 1402, 1484). Version 2.0 additionally detects mutations in the *gyrB* quinolone resistance‐determining region (codons 538, 540) and the *eis* promoter region (codons ‐37, ‐14, ‐12, ‐10, ‐2) ([@CD010705-bbs2-0073]). As mutations in these regions may cause additional resistance to the FQs or SLIDs respectively, MTBDR*sl* version 2.0 should have heightened sensitivity for resistance to these drug classes. Mutations in some regions (for example, the *eis* promoter region) may be responsible for causing resistance to one drug in a class more than other drugs within that class. For example, the *eis* C14T mutation is associated with kanamycin resistance in *M. tuberculosis* strains from Eastern Europe ([@CD010705-bbs2-0069]). MTBDR*sl* version 1.0 also detects mutations in *embB* that may encode for resistance to ethambutol. As this is a first‐line drug and was omitted from MTBDR*sl* version 2.0, we did not determine the accuracy for ethambutol resistance.Table 1Characteristics of MTBDR*sl* versions 1.0 and 2.0**DetectionVersion 1.0: *M. tuberculosis* complex and resistances to FQs, SLIDs, and ethambutolVersion 2.0: *M. tuberculosis* complex and resistances to FQs and SLIDs**SamplesSmear‐positive specimens and culture isolatesSmear‐positive and smear‐negative specimens and culture isolatesFQ resistanceMutations in resistance determining region of the *gyrA* geneMutations in resistance determining regions of the *gyrA* and *gyrB* genesSLID resistanceMutations in resistance determining region of the *rrs* geneMutations in resistance determining region rrs gene and the *eis* promoter regionEthambutol resistanceMutations in the embB geneNot included[^5]

For the FQs, the presence of mutations in each of the genes probed by MTBDR*sl* has high but imperfect concordance with resistance to all drugs within that drug class. For example, a mutation in the *gyrA* gene may mean a strain is resistant to each of the FQs (for example, ofloxacin and moxifloxacin) ([@CD010705-bbs2-0084]). The same holds true for the *rrs* gene and the two aminoglycosides, kanamycin and amikacin ([@CD010705-bbs2-0085]). Evidence is mixed regarding the level of concordance between resistance to the two aminoglycosides and capreomycin arising from mutations in the *rrs* gene. MTBDR*sl* reports on the presence of mutations within these genes (as well as *gyrB* and the *eis* promoter for MTBDR*sl* version 2.0), which are associated with resistance to a class of drugs. The presence of mutation(s) in these regions does not necessarily imply resistance to all the drugs within that class.

For MTBDR*sl* version 1.0, the manufacturer recommended that if the patient specimen (usually sputum) is smear‐positive, the assay be performed on the specimen (direct testing) and if smear‐negative, the assay be performed on the culture isolate grown from the patient specimen (indirect testing). The manufacturer states that MTBDR*sl* version 2.0 may be performed on a smear‐positive or smear‐negative specimen without the need for culture.

The assay procedure involves the following steps: 1. decontamination of the specimen; 2. isolation and amplification of DNA; 3. detection of the amplification products by reverse hybridisation; and 4. visualisation using a streptavidin‐conjugated alkaline phosphatase colour reaction. The observed bands, each corresponding to a probe, can be used to determine the drug susceptibility profile of the analysed specimen. The assay can be completed in five hours.

[Figure 1](#CD010705-fig-0001){ref-type="fig"} shows the line probe assay strips used for MTBDR*sl* version 1.0 or version 2.0. A band for the detection of the *M. tuberculosis* complex (the \"TUB\" band) is included, as well as two internal controls (conjugate and amplification controls) and a control for each gene locus (MTBDR*sl* version 2.0: *gyrA, gyrB, rrs, eis*). The two internal controls plus each gene locus control should be positive; otherwise the assay cannot be evaluated for that particular drug. A result can be indeterminate for one locus but valid for another (on the basis of a gene‐specific locus control failing). A template is supplied by the manufacturer to help read the strips, where the banding patterns are scored by eye, transcribed, and reported. In high‐volume settings, the GenoScan®, an automated reader, can be incorporated to interpret the banding patterns automatically and give a suggested interpretation. If the operator agrees with the interpretation, the results are automatically uploaded, thereby reducing possible transcription errors.Figure 1Comparison of version 1.0 and version 2.0 of the GenoType® MTBDR*sl* test (adapted from [@CD010705-bbs2-0072]).

Clinical pathway {#CD010705-sec2-0003}
----------------

[Figure 2](#CD010705-fig-0002){ref-type="fig"} illustrates the clinical pathway. Depending on the setting, DST is either performed on all patients with confirmed TB or on patients who are clinically suspected of having drug‐resistant TB (for example, if the patients\' symptoms have failed to improve on first‐line therapy, or if they still have *M. tuberculosis* bacilli in their sputum after an extended period of treatment). DST for resistance to the second‐line drugs is usually only performed if resistance to the first‐line drugs is confirmed. Specifically, a patient with suspected drug‐resistant TB provides a specimen (usually sputum), which is examined by smear microscopy. If smear‐positive, MTBDR*sl* version 1.0 or version 2.0 can be performed directly on the specimen. If smear‐negative, MTBDR*sl* version 1.0 should not be performed directly on the specimen, but rather on the culture isolate. MTBDR*sl* version 2.0 may be performed directly on a smear‐negative specimen. A molecular test for first‐line drug resistance (for example, the MTBDR*plus* assay) may be performed prior to testing with MTBDR*sl* if resistance to the first‐line drugs is yet to be confirmed. Phenotypic DST may still be performed on culture‐positive isolates.Figure 2Clinical pathway. A patient to be evaluated for drug‐resistant tuberculosis (TB) provides a specimen (usually sputum), which is examined by smear microscopy. If smear‐positive, MTBDR*sl* version 1.0 or version 2.0 can be performed directly on the specimen. If smear‐negative, MTBDR*sl* version 1.0should not be performed directly on the specimen, but rather on the culture isolate. Version 2.0 may be performed directly on a smear‐negative specimen. A molecular test for first‐line drug resistance (for example, the MTBDR*plus* assay) may be performed prior to testing with MTBDR*sl* if resistance to the first‐line drugs is yet to be confirmed. Phenotypic (culture‐based) drug susceptibility testing (DST) may still be performed on culture‐positive isolates.

### Prior test(s) {#CD010705-sec3-0001}

Patients who received MTBDR*sl* testing may have first received smear microscopy, Xpert® MTB/RIF or another nucleic acid amplification test, and culture to diagnose TB and Xpert® MTB/RIF, MTBDR*plus*, or an alternative line‐probe assay to detect first‐line drug resistance.

### Role of index test(s) {#CD010705-sec3-0002}

The role of MTBDR*sl* would be as the initial test, replacing culture‐based DST, for detecting second‐line drug resistance.

### Alternative test(s) {#CD010705-sec3-0003}

We are aware of several additional line probe assays marketed for genotypic testing for second‐line drug resistance: TB Resistance Module Fluoroquinolones/Ethambutol and TB Resistance  Module Kanamycin/Amikacin/Capreomycin/Streptomycin (Autoimmun Diagnostika GmbH (AID) Strassberg); MolecuTech REBA MTB‐FQ^®^, MolecuTech REBA MTB‐KM^®^, and MolecuTech REBA MTB‐XDR^®^ (YD diagnostics, Seoul); and NiPro LiPA FQ (NiPro Co, Osaka) ([@CD010705-bbs2-0064]). For a comprehensive review of these tests, we refer the reader to the Tuberculosis Diagnostics Technology and Market Landscape report ([@CD010705-bbs2-0064]).

Rationale {#CD010705-sec2-0004}
---------

Second‐line TB drugs are used to treat patients with TB that is resistant to the most effective and widely used first‐line drugs. To ensure that the most appropriate and least toxic drugs are provided to patients as quickly as possible, it is critical to know whether a patient has resistance to FQs alone, resistance to SLIDs alone, or resistance to both FQs and SLIDs (XDR‐TB) as this will guide the selection of drugs. The conventional method for the diagnosis of drug resistance (culture‐based DST) is vulnerable to contamination and loss of viability, meaning that the TB bacteria sometimes cannot be regrown and a culture isolate is hence not available for DST. Culture‐based DST is also slow and can take several months. The resulting diagnostic delay results in unnecessary morbidity, mortality, and increased transmission, which is a major driver of new TB cases. There is a need for rapid assays to improve time‐to‐diagnosis and new molecular assays, such as the MTBDR*sl* assay, present a promising potential solution.

Objectives {#CD010705-sec1-0003}
==========

To assess and compare the diagnostic accuracy of MTBDR*sl* for: 1. fluoroquinolone resistance, 2. SLID resistance, and 3. extensively drug‐resistant tuberculosis, as an indirect test on a *M. tuberculosis* isolate grown from culture or as a direct test on a patient specimen. The populations of interest were people with MDR‐TB or rifampicin‐resistant TB, which is considered a proxy for MDR‐TB in high burden settings, [@CD010705-bbs2-0091].

Secondary objectives {#CD010705-sec2-0005}
--------------------

We planned to investigate heterogeneity in relation to the type of reference standard (culture‐based drug susceptibility testing (DST) compared with sequencing, culture‐based DST and sequencing, and culture‐based DST followed by sequencing of discrepant results) and resistance to individual drugs within a drug class (for example, ofloxacin, moxifloxacin, levofloxacin, and gatifloxacin within the FQ class). We also prespecified in the protocol investigations of heterogeneity in relation to human immunodeficiency virus (HIV) status, condition of the specimen (fresh or frozen, volume of specimen), patient population (patients suspected of having MDR‐TB or XDR‐TB), and whether World Health Organization (WHO)‐recommended critical drug concentrations were used for the culture‐based DST reference standard. Subsequent to the published protocol, we added an investigation of heterogeneity in relation to microscopy smear grade.

Methods {#CD010705-sec1-0004}
=======

Criteria for considering studies for this review {#CD010705-sec2-0006}
------------------------------------------------

### Types of studies {#CD010705-sec3-0004}

We included all studies that determined the diagnostic accuracy of the index test in comparison with a defined reference standard, including case‐control designs. We only included studies from which we could extract data on true positives (TP), false positives (FP), false negatives (FN), and true negatives (TN). We excluded unpublished studies reported only in abstracts and conference proceedings.

### Participants {#CD010705-sec3-0005}

We included patients of any age who had rifampicin‐resistant TB or MDR‐TB or may have had resistance to any of the second‐line TB drugs, irrespective of background burden of drug resistance and patient population.

### Index tests {#CD010705-sec3-0006}

The index test was MTBDR*sl* version 1.0 or version 2.0.

### Target conditions {#CD010705-sec3-0007}

We considered the following target conditions.

Fluoroquinolone (FQ) resistance.Second‐line injectable drug (SLID) resistance.XDR‐TB.

### Reference standards {#CD010705-sec3-0008}

We included studies that used one or more of the following reference standards.

Culture‐based drug susceptibility testing (DST): solid culture or a liquid culture.Sequencing of the *gyrA* or *rrs* genes (MTBDR*sl* version 1.0) or additionally the *gyrB* and *eis* promoter regions (MTBDR*sl* version 2.0).A composite reference standard with two components: culture‐based DST and sequencing of the same samples. If a specimen was resistant according to culture‐based DST or had a mutation, we classified the specimen as having the target condition. If both culture‐based DST and sequencing indicated susceptibility, we classified the specimen as not having the target condition.Two reference standards used sequentially: culture‐based DST followed by selective testing by sequencing of samples with discrepant results. Discrepant results may be either index test positive/culture‐based DST negative or index test negative/culture‐based DST positive.

There are strengths and limitations to each of the reference standards. Culture‐based DST is the accepted reference standard, but it is considered to be imperfect and is dependent on the drug concentration threshold used to define resistance. Sequencing is considered to be more accurate than culture‐based DST; however, this is only if it targets all known resistance‐determining regions, which are not fully known for the FQs and the SLIDs. Therefore, targeted sequencing may miss mutations that cause drug resistance.

We carried out separate analyses for the different reference standards, which we have described below. In our primary analysis we used culture‐based DST as the reference standard. We expected all or nearly all included studies to report results using this reference standard.

Search methods for identification of studies {#CD010705-sec2-0007}
--------------------------------------------

We attempted to identify all relevant studies regardless of language and publication status (published, unpublished, in press, and ongoing).

### Electronic searches {#CD010705-sec3-0009}

Vittoria Lutje (VL), the Information Specialist for the Cochrane Infectious Diseases Group (CIDG), performed literature searches up to 21 September 2015 without language restrictions. To identify all relevant studies, she searched the following databases using the search terms and strategy described in [Appendix 2](#CD010705-sec2-0016){ref-type="app"}: CIDG Specialized Register; MEDLINE (PubMed, 1966 to 21 September 2015); Embase OVID (1980 to 21 September 2015); Science Citation Index Expanded (SCI‐EXPANDED, 1900 to 21 September 2015, Conference Proceedings Citation Index‐Science (CPCI‐S, 1990 to 21 September 2015), and BIOSIS Previews (1926 to 21 September 2015; all three from Web of Science); LILACS (<http://lilacs.bvsalud.org/en/>; 1982 to 21 September 2015); and SCOPUS (1995 to 21 September 2015). She also searched the ISRCTN registry (http://isrctn.com) and the search portal of the World Health Organization International Clinical Trials Registry Platform (ICTRP; <http://apps.who.int/trialsearch/>) to identify ongoing trials, and ProQuest Dissertations & Theses A&I to identify relevant dissertations (all websites accessed on 21 September 2015). We searched MEDION in the previous version of the review, [@CD010705-bbs2-0101], but this database was unavailable in September 2015.

### Searching other resources {#CD010705-sec3-0010}

We reviewed reference lists of included articles and any relevant review articles identified through the above methods. We contacted researchers at FIND and other experts in the field of TB diagnostics for information on ongoing or unpublished studies.

Data collection and analysis {#CD010705-sec2-0008}
----------------------------

### Selection of studies {#CD010705-sec3-0011}

Two review authors (GT and JP) independently scrutinized titles and abstracts identified by electronic literature searches to identify potentially eligible studies. We selected all citations identified as suitable during this screen for full‐text review. The same two review authors then independently reviewed full‐text papers for study eligibility using the predefined inclusion and exclusion criteria. For full‐text articles, we resolved any discrepancies by discussion with a third review author (KRS). We maintained a list of excluded studies and their reasons for exclusion, and recorded these details in the \'[Characteristics of excluded studies](#CD010705-sec2-0026){ref-type="sec"}\' table and prepared a PRISMA diagram.

### Data extraction and management {#CD010705-sec3-0012}

We developed a standardized data extraction form and piloted the form with two of the included studies. Based upon the pilot, we finalized the form. Then two review authors (GT and JP) independently extracted data on the following characteristics and resolved any discrepancies by discussion.

Details of study: first author; publication year; country where testing was performed; specimen country origin; setting (primary care laboratory, hospital laboratory, reference laboratory); study design; manner of participant selection; number of participants enrolled; number of participants for whom results available; industry sponsorship.Characteristics of participants: age; HIV status; smear status; history of TB; known MDR‐TB, pre‐XDR‐TB (defined as MDR‐TB and resistance to a FQ or SLID, but not to drugs from both classes), or XDR‐TB status.Target conditions: resistance to FQ and SLID drug classes and XDR‐TB.Resistances to individual drugs: ofloxacin, moxifloxacin, levofloxacin, gatifloxacin, amikacin, kanamycin, and capreomycin.Reference standards: type; percentage of patients whose reference standard was \'uninterpretable\' (for example, contaminated, sequencing failed).Details of specimen: type (such as expectorated sputum, induced sputum or culture isolate); condition (fresh or frozen); definition of a positive smear; type of testing (direct testing or indirect testing); smear grade (negative, scanty, 1+, 2+, 3+).Details of outcomes: the number of TP, FP, FN, and TN results; number of indeterminate assay results.Intra‐reader and inter‐reader variability.Time to treatment initiation: defined as the time from specimen collection until patient starts treatment.Time to diagnosis: defined as the time from specimen collection until there is an available TB result in lab or clinic, if the assay was performed in a clinic.

We assigned country income status (high, middle or low) as classified by the World Bank List of Economies ([@CD010705-bbs2-0097]). We contacted authors of primary studies for missing data or clarifications. We assigned smear grade according to the WHO definition ([@CD010705-bbs2-0094]). We entered all data into a database manager (Microsoft Excel 2014).

For one study that tested the same panel of TB isolates in multiple centres, we selected one centre that provided results in the middle range (neither the best nor the worst results) ([@CD010705-bbs2-0010]). One study included extrapulmonary specimens, which we excluded from the analysis ([@CD010705-bbs2-0002]). Whenever possible, we extracted data that used a single patient as the unit of analysis (one MTBDR*sl* result per one specimen from one patient).

When culture‐based DST was performed using more than one drug from the FQs (ofloxacin, moxifloxacin, levofloxacin, or gatifloxacin) or SLIDs (amikacin, kanamycin or capreomycin), we extracted TP, FP, FN, and TN values for each drug and for each class overall. If the reference standard indicated resistance for at least one drug in that class, we classified the sample as resistant to that class of drugs. We did not require reference standard DST results for all drugs in a class in order to classify a sample as resistant or susceptible.

In the 2 x 2 tables of TP, FP, FN, and TN, we based the results of the index test on categorical assay results defined by the visual readout of the MTBDR*sl* strip.

#### Possible results for the GenoType® MTBDR*sl* assay (as defined by the product manual) {#CD010705-sec4-0001}

Sensitive to either FQs or SLIDs (referred to as \'aminoglycosides/cyclic peptides\'), or both (conjugation and amplification bands present; *Mycobacterium tuberculosis* complex‐specific control (TUB) band present; gene locus band present; all wild type (*wt*) bands for each gene present; no mutation bands present). In the case of susceptibility to both drug classes, the test would indicate susceptibility for each, rather than having a single composite readout specifying XDR‐TB.Resistant to either FQs or SLIDs, or both (conjugation and amplification bands present; TUB band present; gene locus band present; all, none or some *wt* bands for each gene present; all, none or some mutation bands present with similar intensity to amplification control). In the case of resistance to both drug classes, the test would indicate resistance for each, rather than having a composite readout.Indeterminate (faint bands) or no result (no conjugation or amplification bands present, no locus band present for the gene of interest).No TB (negative for MTB complex irrespective of locus control band).No result (failure of any one of the control bands, as well as the TUB band).

No studies reported on the number of \'no TB\' or \'no result\' results obtained from MTBDR*sl*, therefore we only extracted the number and percentage of \'indeterminate\' results.

#### Assignment of results to the fluoroquinolones, second‐line injectable drugs, or both categories {#CD010705-sec4-0002}

We were able to report accuracy estimates for individual drugs within the drug classes when that drug was used as part of the culture‐based DST reference standard. For determining resistance to the drug class, we used the following approach. For a culture‐based DST reference standard, one study might have used detection of ofloxacin resistance and another study, detection of moxifloxacin resistance to confirm an MTBDR*sl* FQ‐resistant result. In such a scenario, if culture‐based DST is positive for resistance to one of the drugs in the drug class and the MTBDR*sl* result is concordant, we classified the index test result as a true positive for resistance to the FQs. We adopted the same approach for the SLIDs.

For sequencing as a reference standard, if the index test reported resistance to FQs and the presence of mutations known to be associated with drug resistance to the FQs was confirmed in the same regions of the genome targeted by MTBDR*sl*, we recorded the test result as concordant and classified the index test as a true positive for resistance to the FQs. We adopted the same approach for the SLIDs.

### Assessment of methodological quality {#CD010705-sec3-0013}

We appraised the quality of the included studies with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool ([@CD010705-bbs2-0090]; [Appendix 3](#CD010705-sec2-0017){ref-type="app"}). QUADAS‐2 consists of four domains: patient selection, index test, reference standard, and flow and timing. We assessed all domains for risk of bias and the first three domains for concerns regarding applicability. We used signalling questions in each domain to form judgments about the risk of bias. One review author (GT) piloted the tool with two included studies and finalized the tool based on experience gained from the pilot testing. Three review authors (GT, JP, and KRS) then independently assessed the methodological quality of included studies with the finalized tool and finalized judgments by discussion.

### Statistical analysis and data synthesis {#CD010705-sec3-0014}

We performed descriptive analyses for key variables (such as country income status) of the primary studies using Stata ([@CD010705-bbs2-0086]), and displayed key study characteristics in the \'[Characteristics of included studies](#CD010705-sec2-0025){ref-type="sec"}\' table.

We analysed data separately for MTBDR*sl* version 1.0 and version 2.0. We used the reference standard culture‐based DST in our primary analyses. We stratified these analyses first by target condition and second by type of MTBDR*sl* testing (indirect testing or direct testing). Within each stratum (for example, FQ resistance by indirect testing), we plotted estimates of the studies\' observed sensitivities and specificities in forest plots with 95% confidence intervals (CIs) and in receiver operating characteristic (ROC) space using Review Manager (RevMan) ([@CD010705-bbs2-0081]). Where adequate data were available, we combined data using meta‐analysis. We performed most meta‐analyses by fitting the bivariate random‐effects model ([@CD010705-bbs2-0074]; [@CD010705-bbs2-0080]), using Stata with the metandi and xtmelogit commands ([@CD010705-bbs2-0086]). In situations with few studies, we performed meta‐analysis where appropriate by reducing the bivariate model to two univariate random‐effects logistic regression models by assuming no correlation between sensitivity and specificity. When we observed little or no heterogeneity on forest plots and summary receiver operating characteristic (SROC) plots, we further simplified the models into fixed‐effect models by eliminating the random‐effects parameters for sensitivity or specificity, or both sensitivity and specificity ([@CD010705-bbs2-0089]).

We compared results from studies of direct testing with results from studies of indirect testing by adding a covariate for the type of testing to the model. We assessed the significance of the differences in sensitivity and specificity estimates between studies in which MTBDR*sl* was performed by direct testing or indirect testing by a likelihood ratio test comparing models with and without covariate terms. Where data were sufficient, we performed comparative analyses including only those studies that made direct comparisons between test evaluations with the same participants. Otherwise, we included all studies with available data. Comparative studies are preferred to non‐comparative studies when deriving evidence of diagnostic test accuracy ([@CD010705-bbs2-0088]).

#### Approach to uninterpretable (indeterminate) MTBDR*sl* results {#CD010705-sec4-0003}

We excluded indeterminate test results from the analyses for determination of sensitivity and specificity. We determined the percentage of indeterminate MTBDR*sl* results among the primary studies for each target condition and summarized these findings separately for indirect and direct testing when available, according to culture‐based reference standard.

### Investigations of heterogeneity {#CD010705-sec3-0015}

Within each stratum (for example, SLID resistance, indirect testing), we investigated heterogeneity through visual examination of forest plots of sensitivity and specificity. Then, if sufficient studies were available, we explored the possible influence of the following prespecified categorical covariates: reference standard (culture, sequencing, culture and sequencing, culture followed by sequencing); resistance to the following drugs: ofloxacin, moxifloxacin, levofloxacin, gatifloxacin, amikacin, kanamycin, and capreomycin (we excluded resistance to ciprofloxacin because this drug is infrequently used in DST); and drug concentration used for culture‐based DST (WHO‐recommended critical concentration used or a different concentration used). In addition, for this updated review, we added an investigation of heterogeneity in relation to microscopy smear grade. We assessed the significance of the difference in test accuracy (for example, between studies using culture versus those using sequencing as the reference standard) by a likelihood ratio test comparing models with and without covariate terms.

We had planned to investigate the effect of HIV status, the condition of the specimen (fresh or frozen), sample volume, and population (patients thought to have MDR‐TB or XDR‐TB) on summary estimates of sensitivity and specificity in a meta‐regression analysis by adding covariate terms to the bivariate model. However, there were insufficient data for these additional analyses.

### Sensitivity analyses {#CD010705-sec3-0016}

For our primary analyses using the culture‐based DST reference standard, we performed sensitivity analyses for QUADAS‐2 items to explore whether the accuracy estimates were robust with respect to the methodological quality of the studies. We included the following signalling questions.

Was a consecutive or random sample of patients/specimens enrolled?Was a case‐control design avoided?Were the index test results interpreted without knowledge of the results of the reference standard?Was the test applied in the manner recommended by the manufacturer (index test domain, low concern about applicability)?

### Assessment of reporting bias {#CD010705-sec3-0017}

We did not undertake a formal assessment of publication bias of data included in this review using methods such as funnel plots or regression tests because such techniques have been unhelpful for determining publication bias within diagnostic test accuracy studies ([@CD010705-bbs2-0074]).                                                             

#### Other analyses {#CD010705-sec4-0004}

We had intended to summarize data on intra‐ and inter‐reader variability; however inter‐reader variability was the only information described in the included studies. We had also intended to summarize two patient outcomes, time‐to‐diagnosis, and time‐to‐treatment initiation; however time‐to‐diagnosis was the only outcome described in the included studies.

#### Assessment of the quality of evidence (certainty of the evidence) {#CD010705-sec4-0005}

We assessed the quality of evidence (also called certainty of the evidence or confidence in effect estimates) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach ([@CD010705-bbs2-0060]; [@CD010705-bbs2-0070]), and GRADEpro Guideline Development Tool (GDT) software ([@CD010705-bbs2-0071]). In the context of a systematic review, the ratings of the certainty of the evidence reflect the extent of our confidence that the estimates of the effect (including test accuracy and associations) are correct. As recommended, we rated the quality of evidence as either high (not downgraded), moderate (downgraded by one level), low (downgraded by two levels), or very low (downgraded by more than two levels) for five domains: risk of bias, indirectness, inconsistency, imprecision, and publication bias. For each outcome, the quality of evidence started as high when there were high quality observational studies (cross‐sectional or cohort studies) that enrolled participants with diagnostic uncertainty. If we found a reason for downgrading, we used our judgement to classify the reason as either serious (downgraded by one level) or very serious (downgraded by two levels).

Three review authors (GT, JP, and KRS) discussed judgments and applied GRADE in the following way.

Risk of bias: we used QUADAS‐2 to assess risk of bias.Indirectness: we considered indirectness from the perspective of test accuracy. We used QUADAS‐2 for concerns of applicability and looked for important differences between the populations studied (for example, in the spectrum of disease), the setting, and the review questions.Inconsistency: GRADE recommends downgrading for unexplained inconsistency in sensitivity and specificity estimates. We carried out prespecified analyses to investigate potential sources of heterogeneity and did not downgrade the quality of the evidence when we felt we could explain inconsistency in the accuracy estimates.Imprecision: we considered a precise estimate to be one that would allow a clinically meaningful decision. We considered the width of the CI, and asked ourselves, "Would we make a different decision if the lower or upper boundary of the CI represented the truth?" In addition, we worked out projected ranges for TP, FN, TN, and FP for a given TB prevalence and made judgements on imprecision from these calculations.Publication bias: we rated publication bias as undetected (not serious) because of the comprehensiveness of the literature search and extensive outreach to TB researchers to identify studies.

Results {#CD010705-sec1-0005}
=======

Results of the search {#CD010705-sec2-0009}
---------------------

We identified 27 unique studies that met the inclusion criteria of this review. All studies but two ([@CD010705-bbs2-0006], written in Chinese and [@CD010705-bbs2-0005], written in Japanese) were written in English. For MTBDR*sl* version 1.0, we included 26 studies: 21 studies from [@CD010705-bbs2-0101], the original Cochrane review ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]; [@CD010705-bbs2-0003]; [@CD010705-bbs2-0005]; [@CD010705-bbs2-0006]; [@CD010705-bbs2-0007]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0009]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0011]; [@CD010705-bbs2-0014]; [@CD010705-bbs2-0015]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0017]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0022]; [@CD010705-bbs2-0025]; [@CD010705-bbs2-0026]; [@CD010705-bbs2-0027]) and five new studies ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0013]; [@CD010705-bbs2-0021]; [@CD010705-bbs2-0024]). For MTBDR*sl* version 2.0, we included one study ([@CD010705-bbs2-0023]). [Figure 3](#CD010705-fig-0003){ref-type="fig"} shows the flow of studies in the review. We recorded the excluded studies and the reasons for their exclusion in the \'[Characteristics of excluded studies](#CD010705-sec2-0026){ref-type="sec"}\' table.Figure 3Study flow diagram for searches run from January 2014 to 21 September 2015.

Methodological quality of included studies {#CD010705-sec2-0010}
------------------------------------------

[Figure 4](#CD010705-fig-0004){ref-type="fig"} and [Figure 5](#CD010705-fig-0005){ref-type="fig"} show risk of bias and applicability concerns for each of the 27 included studies. In the patient selection domain, we judged that 17 studies (63%) had low risk of bias ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0007]; [@CD010705-bbs2-0009][@CD010705-bbs2-0011]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0013]; [@CD010705-bbs2-0015]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0017]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0021]; [@CD010705-bbs2-0022]; [@CD010705-bbs2-0023]; [@CD010705-bbs2-0025]; [@CD010705-bbs2-0027]). We judged that one study (4%) had unclear risk of bias because the manner of patient selection was unclear ([@CD010705-bbs2-0005]). We judged that nine studies had high risk of bias for the following reasons.Figure 4Risk of bias and applicability concerns graph: review authors\' judgements about each domain presented as percentages across included studies.Figure 5Risk of bias and applicability concerns summary: review authors\' judgements about each domain for each included study.For direct testing of smear‐positive specimens, [@CD010705-bbs2-0019] and [@CD010705-bbs2-0024] had low risk of bias in the patient selection domain.

There was a case‐control design (four studies: [@CD010705-bbs2-0003]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0014]).There was a cross‐sectional design for samples used in direct testing and case‐control design for samples used in indirect testing (two studies: [@CD010705-bbs2-0019]; [@CD010705-bbs2-0024]).Enrolment was by convenience (three studies: [@CD010705-bbs2-0006]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0026]).

Regarding applicability (patient characteristics and setting), we judged that 21 studies (78%) had low concern and six studies had high concern ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0014]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0026]). In the index test domain, we judged that 18 studies (67%) had low risk of bias ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0009]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0011]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0013]; [@CD010705-bbs2-0015]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0017]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0021]; [@CD010705-bbs2-0023]; [@CD010705-bbs2-0024]; [@CD010705-bbs2-0026]; [@CD010705-bbs2-0027]); seven (26%) studies had unclear risk of bias because information about blinding was not reported ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0006]; [@CD010705-bbs2-0007]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0022]; [@CD010705-bbs2-0025]); and two studies had high risk of bias because the index test results were not interpreted without knowledge of the reference standard results ([@CD010705-bbs2-0005]; [@CD010705-bbs2-0014]). Regarding applicability of the index test, we judged that 24 studies (89%) had low concern, one study (4%) had high concern ([@CD010705-bbs2-0004]), and two studies had unclear concern ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0025]).

In the reference standard domain, we judged that only three studies (11%) had low risk of bias ([@CD010705-bbs2-0013]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0024]) because these studies used the WHO‐recommended critical concentration for each drug included in the culture‐based drug susceptibility testing (DST) reference standard; 18 studies (67%) had unclear risk of bias ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0009]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0006]; [@CD010705-bbs2-0007]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0015]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0021]; [@CD010705-bbs2-0022]; [@CD010705-bbs2-0023]; [@CD010705-bbs2-0025]; [@CD010705-bbs2-0027]), because these studies used the World Health Organization (WHO)‐recommended critical concentration for some, but not all of the drugs included in the culture‐based DST reference standard; and six studies had high risk of bias ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0005]; [@CD010705-bbs2-0011]; [@CD010705-bbs2-0014]; [@CD010705-bbs2-0017]; [@CD010705-bbs2-0026]) because these studies did not use WHO‐recommended critical concentrations for any of the drugs included in the culture‐based DST reference standard. Regarding applicability of the reference standard, we judged that all studies had low concern. In the flow and timing domain, we judged that 26 studies (96%) had low risk of bias and one study had unclear risk of bias because we could not account for all patients in the analyses ([@CD010705-bbs2-0007]).

We noted industry involvement in eight studies (30%) and this included the following.

Donation of MTBDR*sl* (five studies: [@CD010705-bbs2-0007]; [@CD010705-bbs2-0008]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0022]; [@CD010705-bbs2-0023]).Preferred pricing of MTBDR*sl* (one study: [@CD010705-bbs2-0002]).Financial support for non‐test related study costs (one study: [@CD010705-bbs2-0020]).Involvement in the design, analysis or manuscript production (one study: [@CD010705-bbs2-0001]).

Findings {#CD010705-sec2-0011}
--------

We presented key characteristics of the 27 included studies in the \'[Characteristics of included studies](#CD010705-sec2-0025){ref-type="sec"}\' table. Of 26 studies reporting specimen country origin, 15 studies (58%) evaluated patients from low‐ or middle‐income countries. The median sample size (interquartile range) was 95 (44 to 176).

### MTBDRsl version 1.0 {#CD010705-sec3-0018}

[Table 6](#CD010705-tbl-0006){ref-type="table"} (indirect testing) and [Table 7](#CD010705-tbl-0007){ref-type="table"} (direct testing) show the number of studies that evaluated MTBDR*sl* version 1.0, according to the reference standard and target condition. We did not identify any studies that evaluated the accuracy of MTBDR*sl* for gatifloxacin resistance.Table 2Map of review showing the number of studies evaluating MTBDR*sl* version 1.0 by indirect testing, according to the reference standard and target condition**Target condition, drug resistance to\...Reference standardCulture, n/N (%)Sequencing, n/N (%)Sequencing and culture, n/N (%)Culture followed by sequencing of discrepant results, n/N (%)**FQs19/19 (100)^1^7/19 (37)7/19 (37)3/19 (16)Ofloxacin13/19 (68)000Moxifloxacin6/19 (32)000Levofloxacin2/19 (11)000SLIDs16/16 (100)^1^7/16 (44)7/16 (44)3/16 (19)Amikacin11/16 (69)000Kanamycin9/16 (56)000Capreomycin10/16 (63)000XDR‐TB8/8 (100)3/8 (38)2/8 (25)0[^6]Table 3Map of review showing the number of studies evaluating MTBDR*sl* version 1.0 by direct testing, according to the reference standard and target condition**Target condition, drug resistance to\...Reference standardCulture, n/N (%)Sequencing, n/N (%)Sequencing and culture, n/N (%)Culture followed by sequencing of discrepant results, n/N (%)**FQs9/9 (100)^1^002/9 (22)Ofloxacin7/9 (78)002/9 (11)Moxifloxacin2/9 (22)000Levofloxacin0000Gatifloxacin0000SLIDs8/8 (100)^1^002/8 (25)Amikacin6/8 (75)001/8 (13)Kanamycin5/8 (63)000Capreomycin5/8 (63)000XDR‐TB6/6 (100)002/6 (33)[^7]

### I. Fluoroquinolone resistance detection {#CD010705-sec3-0019}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0006}

##### 1. Indirect testing {#CD010705-sec5-0001}

Nineteen studies (2223 participants, 869 (39.1%) confirmed cases of fluoroquinolone (FQ)‐resistant TB) evaluated MTBDR*sl* by indirect testing for detection of FQ resistance ([Figure 6](#CD010705-fig-0006){ref-type="fig"}). Sensitivity estimates ranged from 57% to 100% and specificity estimates ranged from 77% to 100%. The pooled sensitivity and specificity (95% CI) were 85.6% (79.2% to 90.4%) and 98.5% (95.7% to 99.5%) ([Table 8](#CD010705-tbl-0008){ref-type="table"}).Figure 6Forest plots of MTBDR*sl* sensitivity and specificity for fluoroquinolone (FQ) resistance, the test performed indirectly or directly against culture‐based drug susceptibility (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.Table 4Accuracy of MTBDR*sl* version 1.0 for resistance to FQs and SLIDs and XDR‐TB, by type of testing, culture‐based DST reference standard**Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity P value^1^Pooled specificity P value^1^FQs, indirect testing**\
(19 studies, 2223 participants)**FQs, direct testing**\
(9 studies, 1771 participants)0.9320.33385.6% (79.2 to 90.4)98.5% (95.7 to 99.5)86.2% (74.6 to 93.0)98.6% (96.9 to 99.4)**SLIDs, indirect testing**\
(16 studies, 1921 participants)**SLIDs, direct testing**\
(8 studies, 1639 participants)0.5470.66476.5% (63.3 to 86.0)99.1% (97.3 to 99.7)87.0% (38.1 to 98.6)99.5% (93.6 to 100.0)**XDR‐TB, indirect testing**\
(8 studies, 880 participants)**XDR‐TB, direct testing**\
(6 studies, 1420 participants)0.8880.85570.9% (42.9 to 88.7)98.8% (96.1 to 99.6)69.4% (38.8 to 89.0)99.4% (95.0 to 99.3)[^8]

##### 2. Direct testing {#CD010705-sec5-0002}

Nine studies (1771 participants, 519 (29.3%) confirmed cases of FQ‐resistant TB) evaluated MTBDR*sl* by direct testing for detection of FQ resistance, ([Figure 6](#CD010705-fig-0006){ref-type="fig"}). Sensitivity estimates ranged from 33% to 100% and specificity estimates ranged from 91% to 100%. The pooled sensitivity and specificity (95% CI) were 86.2% (74.6% to 93.0%) and 98.6% (96.9% to 99.4%) ([Table 8](#CD010705-tbl-0008){ref-type="table"}).

##### 3. Comparison of indirect versus direct testing {#CD010705-sec5-0003}

###### (a) Diagnostic accuracy {#CD010705-sec6-0001}

Based on analysis of all data, there was no evidence of a statistically significant difference in MTBDR*sl* version 1.0 accuracy for FQ resistance between indirect and direct testing (smear‐positive specimen) when using culture‐based DST as a reference standard (P values for differences in sensitivity and specificity of 0.932 and 0.333, respectively) ([Table 8](#CD010705-tbl-0008){ref-type="table"}). Direct within‐study comparisons were not possible because no studies performed MTBDR*sl* testing on specimens and isolates from the same patients.

###### (b) Indeterminate rates {#CD010705-sec6-0002}

MTBDR*sl* version 1.0: for indirect testing for culture‐confirmed resistance to FQs, of 14 studies that reported indeterminate MTBDR*sl* results, eight of 2065 results (0.4%) were indeterminate (seven culture‐DST resistant and one culture‐DST sensitive). For direct testing on a smear‐positive specimen, of nine studies that reported indeterminate MTBDR*sl* results, 147 of 2059 results (7.1%) were indeterminate (68 culture‐DST resistant, 73 susceptible, and six whose culture phenotypic status was unknown). The indeterminate rates for direct testing for each smear‐grade (smear‐negative, scanty, 1+, 2+, 3+) were 61/190 (32.1%), 28/133 (21.1%), 35/272 (12.9%), 19/211 (9.0%), and 44/388 (11%), respectively.

#### B. Investigations of heterogeneity {#CD010705-sec4-0007}

##### 1. Indirect testing {#CD010705-sec5-0004}

###### (a) Individual drugs within the drug class {#CD010705-sec6-0003}

We present accuracy estimates for MTBDR*sl* by indirect testing for detection of resistance to ofloxacin, moxifloxacin, and levofloxacin in [Table 9](#CD010705-tbl-0009){ref-type="table"} and [Appendix 4](#CD010705-sec2-0018){ref-type="app"}.Table 5Accuracy of MTBDR*sl* version 1.0 for resistance to select FQ and SLID drugs, culture‐based DST reference standard**Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity P value^1^Pooled specificity P value^1^Ofloxacin, indirect testing**\
(13 studies, 1927 participants)**Ofloxacin, direct testing**\
(7 studies, 1667 participants)0.1800.16185.2% (78.5 to 90.1)98.5% (95.6 to 99.5)90.9% (84.7 to 94.7)98.9% (97.8 to 99.4)**Moxifloxacin, indirect testing**\
(6 studies, 419 participants)**Moxifloxacin, direct testing**\
(2 studies, 821 participants)0.8200.36594.0% (82.2 to 98.1)96.6% (85.2 to 99.3)95.0% (92.1 to 96.9)99.0% (97.5 to 99.6)**Levofloxacin, indirect testing^2^**\
(2 studies, 169 participants)**Levofloxacin, direct testing**\
(0 studies, 0 participants)Not applicableNot applicableNot applicableNot applicableNot applicableNot applicable**Amikacin, indirect testing**\
(11 studies, 1301 participants)**Amikacin, direct testing**\
(6 studies, 1491 participants)0.3380.21384.9% (79.2 to 89.1)99.1% (97.6 to 99.6)91.9% (71.5 to 98.1)99.9% (95.2 to 100.0)**Kanamycin, indirect testing**\
(9 studies, 1342 participants)**Kanamycin, direct testing**\
(5 studies, 1020 participants0.8360.44566.9% (44.1 to 83.8)98.6% (96.1 to 99.5)78.7% (11.9 to 99.0)99.7% (93.8 to 100.0)**Capreomycin, indirect testing**\
(10 studies, 1406 participants**Capreomycin, direct testing**\
(5 studies, 1027 participants)0.8410.35379.5% (58.3 to 91.4)95.8% (93.4 to 97.3)76.6% (61.1 to 87.3)98.2% (92.5 to 99.6)[^9]

For detection of ofloxacin resistance by indirect testing, sensitivity estimates ranged from 70% to 100% and specificity estimates ranged from 91% to 100%. The pooled sensitivity and specificity (95% CI) were 85.2% (78.5% to 90.1%) and 98.5% (95.6% to 99.5%), (13 studies, 1927 participants).

For detection of moxifloxacin resistance by indirect testing, sensitivity estimates ranged from 57% to 100% and specificity estimates from 77% to 100%. The pooled sensitivity and specificity (95% CI) were 94.0% (82.2% to 98.1%) and 96.6% (85.2% to 99.3%), (six studies, 419 participants).

We identified two studies for detection of levofloxacin resistance by indirect testing. Sensitivity and specificity estimates (95% CI) were 80% (56% to 94%) and 96% (80% to 100%) for [@CD010705-bbs2-0005], and 100% (96% to 100%) and 100% (88% to 100%) for [@CD010705-bbs2-0013]. We did not determine summary estimates because there were only two studies and the sensitivity was variable.

###### (b) Drug concentration used in culture‐based DST {#CD010705-sec6-0004}

[Appendix 5](#CD010705-sec2-0019){ref-type="app"} shows ofloxacin, levofloxacin, and moxifloxacin drug concentrations used in culture‐based DST in relation to the WHO‐recommended critical concentrations.

Ofloxacin: eight studies used the WHO‐recommended critical concentration of ofloxacin ([@CD010705-bbs2-0006]; [@CD010705-bbs2-0009]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0024]), whereas two did not ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0014]). Two studies used two different types of culture medium but only used the WHO‐recommended critical concentration of ofloxacin for one type of culture medium ([@CD010705-bbs2-0008]; [@CD010705-bbs2-0027]). [@CD010705-bbs2-0011] used a non‐WHO recommended concentration for one type of culture medium and no recommended concentration existed for the other culture type. There was no evidence of a statistically significant difference in MTBDR*sl* version 1.0 accuracy for ofloxacin resistance between studies that did or did not use the WHO‐recommended critical concentration (P values for differences in sensitivity and specificity of 0.960 and 0.904, respectively).

Moxifloxacin: [@CD010705-bbs2-0007] used the WHO‐recommended critical concentration for low‐level moxifloxacin resistance whereas [@CD010705-bbs2-0017] used the concentration recommended for high‐level resistance. Four studies did not use the recommended critical concentration of moxifloxacin ([@CD010705-bbs2-0006]; [@CD010705-bbs2-0012]; [@CD010705-bbs2-0021]; [@CD010705-bbs2-0026]).

Levofloxacin: one study used the WHO‐recommended critical concentration ([@CD010705-bbs2-0013]), and one study ([@CD010705-bbs2-0005]) used a culture media type for which a recommended concentration does not exist.

Comparisons between accuracy estimates for moxifloxacin and levofloxacin according to critical concentration were not possible given the small number of studies.

###### (c) Type of reference standard {#CD010705-sec6-0005}

We present MTBDR*sl* accuracy estimates for detection of FQ resistance against different reference standards in [Table 10](#CD010705-tbl-0010){ref-type="table"} and [Appendix 6](#CD010705-sec2-0020){ref-type="app"}.Table 6Accuracy of MTBDR*sl* version 1.0 by indirect testing for FQ and SLID resistance and XDR‐TB, by reference standard**Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity (95% CI)Pooled specificity (95% CI)Pooled sensitivity P value^1^Pooled specificity P value^1^FQ, culture**\
(6 studies, 873 participants)**FQ, sequencing**\
(6 studies, 873 participants)\< 0.0010.73582.4% (77.6 to 86.3)98.8% (94.3 to 99.8)99.3% (81.2 to 100.0)99.3% (90.8 to 100)**FQ, culture**\
(7 studies, 1211 participants)**FQ, sequencing and culture**\
(7 studies, 1211 participants)0.6640.07081.8% (77.2 to 85.7)99.0% (95.0 to 99.8)82.0% (77.7 to 85.6)99.8% (98.5 to 100)**SLIDs, culture**\
(6 studies, 873 participants)**SLIDs sequencing**\
(6 studies, 873 participants)0.0340.45674.6% (66.2 to 81.5)99.9% (71.8 to 100.0)97.0% (77.0 to 99.7)99.5% (94.5 to 100.0)**SLIDs, culture**\
(6 studies, 1159 participants)**SLIDs, sequencing and culture**\
(6 studies, 1159 participants)0.4580.20370.5% (52.0 to 84.1)99.8% (93.8 to 100.0)61.3% (45.8 to 74.8%)99.9% (99.0 to 100.0)**XDR‐TB, culture**\
(8 studies, 880 participants)**XDR‐TB, sequencing**^2^\
(4 studies, 630 participants)Could not determineCould not determine70.9% (42.9 to 88.8)98.8% (96.1 to 99.6)100% (94.6 to 100.0)97.9% (96.3 to 98.8)[^10]

[Reference standard is sequencing]{.ul}

Using sequencing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 85% to 100% and specificity estimates ranged from 92% to 100%. Based on comparative studies, the pooled sensitivity and specificity (95% CI) were 99.3% (81.2% to 100.0%) and 99.3% (90.8% to 100.0%), (six studies, 873 participants). There was evidence of a significantly higher sensitivity using sequencing as the reference standard compared with culture‐based DST (P value \< 0.001), but not specificity (P value of 0.735).

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

Using culture and sequencing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 74% to 91% and specificity estimates ranged from 99% to 100%. Based on comparative studies, the pooled sensitivity and specificity (95% CI) were 82.0% (77.7% to 85.6%) and 99.8% (98.5% to 100.0%), (seven studies, 1211 participants). There was no evidence of a statistically significant difference using both culture‐based DST and sequencing as the reference standard compared with culture‐based DST (P values for differences in sensitivity and specificity of 0.664 and 0.070, respectively).

[Reference standard is culture‐based DST followed by sequencing of discrepant index test‐culture‐based DST results]{.ul}

Using sequencing of discrepant results, MTBDR*sl* version 1.0 sensitivity estimates ranged from 73% to 100% and specificity estimates ranged from 94% to 100%. The pooled sensitivity and specificity (95% CI) were 83.7% (74.2% to 90.8%) and 99.7% (98.4% to 100.0%), (three studies, 427 participants). We did not perform within study comparisons between accuracy estimates using this reference standard and culture‐based DST given the small number of studies in the former group.

##### 2. Direct testing {#CD010705-sec5-0005}

###### (a) Individual drugs within the drug class {#CD010705-sec6-0006}

We present accuracy estimates for MTBDR*sl* version 1.0 by direct testing for detection of resistance to ofloxacin and moxifloxacin in [Table 9](#CD010705-tbl-0009){ref-type="table"} and [Appendix 7](#CD010705-sec2-0021){ref-type="app"}. We did not identify any studies that performed direct testing for detection for levofloxacin resistance.

For detection of ofloxacin resistance by direct testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 79% to 100% and specificity estimates ranged from 98% to 100%, (seven studies, 1667 participants). The pooled sensitivity and specificity (95% CI) were 90.9% (84.7% to 94.7%) and 98.9% (97.8% to 99.4%). Based on all data, there was no evidence of a statistically significant difference between indirect and direct testing for ofloxacin resistance (P values for differences in sensitivity and specificity of 0.180 and 0.161, respectively).

For detection of moxifloxacin resistance by direct testing, [@CD010705-bbs2-0004] reported MTBDR*sl* version 1.0 sensitivity of 96% and specificity of 99% and [@CD010705-bbs2-0001] reported a sensitivity of 92% and specificity of 98%. The pooled sensitivity and specificity (95% CI) were 95.0% (92.1% to 96.9%) and 99.0% (95% CI 97.5% to 99.6%), (two studies, 821 participants). Based on all data, there was no evidence of a statistically significant difference between indirect and direct testing for moxifloxacin resistance (P values for differences in sensitivity and specificity of 0.820 and 0.365, respectively).

###### (b) Drug concentration used in culture‐based DST {#CD010705-sec6-0007}

[Appendix 5](#CD010705-sec2-0019){ref-type="app"} shows ofloxacin and moxifloxacin drug concentrations used in culture‐based DST in relation to the WHO‐recommended critical concentrations.

Ofloxacin: five studies used the WHO‐recommended critical concentration of ofloxacin ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]: [@CD010705-bbs2-0004]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0024]), whereas one study did not ([@CD010705-bbs2-0025]). [@CD010705-bbs2-0008], which used two types of culture medium, used the recommended concentration for one culture type and a non‐recommended concentration for the other.

Moxifloxacin: neither study used the WHO‐recommended critical concentration of moxifloxacin ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0004]).

Comparisons between accuracy estimates according to whether or not WHO‐recommended critical drug concentrations were used for culture‐based reference testing were not possible given the small number of studies.

###### (c) Stratification by smear grade {#CD010705-sec6-0008}

There were limited data on MTBDR*sl* version 1.0 accuracy for individual FQ drugs by smear grade. [Figure 7](#CD010705-fig-0007){ref-type="fig"} presents the forest plots for ofloxacin resistance by smear grade.Figure 7Forest plots of MTBDR*sl* sensitivity and specificity for ofloxacin resistance by smear grade, using culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

###### (d) Type of reference standard {#CD010705-sec6-0009}

[Reference standard is sequencing]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing and used sequencing as a reference standard.

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing and used both culture‐based DST and sequencing (performed on all isolates) as a reference standard.

[Reference standard is culture‐based DST followed by sequencing of discrepant index test‐culture‐based DST results]{.ul}

Two studies (685 participants) reported MTBDR*sl* version 1.0 sensitivity and specificity when performed directly for the detection of resistance to FQs, with culture‐based DST and sequencing performed only on discrepant results as a reference standard. The reported sensitivity and specificity (95% CI) were 91% (84% to 96%) and 98% (92% and 100%) for [@CD010705-bbs2-0001], and 96% (88% to 100%) and 99% (98% to 100%) for [@CD010705-bbs2-0002].

### II. Second‐line injectable drug resistance detection {#CD010705-sec3-0020}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0008}

##### 1. Indirect testing {#CD010705-sec5-0006}

Sixteen studies (1921 participants, 575 (29.9%) confirmed cases of second‐line injectable drug (SLID)‐resistant TB) evaluated MTBDR*sl* version 1.0 by indirect testing for detection of SLID resistance ([Figure 8](#CD010705-fig-0008){ref-type="fig"}). Sensitivity estimates ranged from 25% to 100% and specificity estimates ranged from 86% to 100%. The pooled sensitivity and specificity (95% CI) were 76.5% (63.3% to 86.0%) and 99.1% (97.3% to 99.7%) ([Table 8](#CD010705-tbl-0008){ref-type="table"}).Figure 8Forest plots of MTBDR*sl* sensitivity and specificity for SLID resistance, the test performed indirectly or directly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

##### 2. Direct testing {#CD010705-sec5-0007}

Eight studies (1639 participants, 348 (21.2%) confirmed cases of FQ‐resistant TB) evaluated MTBDR*sl* version 1.0 by direct testing for detection of SLID resistance ([Figure 8](#CD010705-fig-0008){ref-type="fig"}). For individual studies, sensitivity estimates ranged from 9% to 100% and specificity estimates ranged from 58% to 100%. The pooled sensitivity and specificity (95% CI) were 87.0% (38.1% to 98.6%) and 99.5% (93.6% to 100.0%) ([Table 8](#CD010705-tbl-0008){ref-type="table"}).

##### 3. Comparison of indirect versus direct testing {#CD010705-sec5-0008}

###### (a) Diagnostic accuracy {#CD010705-sec6-0010}

Based on analysis of all data, there was no evidence of a statistically significant difference in MTBDR*sl* version 1.0 accuracy for SLID resistance between indirect and direct testing when using culture‐based DST as a reference standard (P values for differences in sensitivity or specificity of 0.547 and 0.664, respectively) ([Table 8](#CD010705-tbl-0008){ref-type="table"}). Direct within‐study comparisons were not possible because no studies performed MTBDR*sl* testing on specimens and isolates from the same patients.

###### (b) Indeterminate rates {#CD010705-sec6-0011}

For indirect testing for culture‐confirmed resistance to SLIDs, of 10 studies that reported indeterminate MTBDR*sl* version 1.0 results, seven (0.5%) of 1316 results were indeterminate (two culture‐DST resistant and five culture‐DST sensitive). For direct testing on a smear‐positive specimen, of four studies that reported indeterminate MTBDR*sl* results, 219 (13.5%) of 1627 results were indeterminate (34 were culture‐DST resistant, 165 were culture‐DST susceptible, and 20 whose culture phenotypic status was unknown). The indeterminate rates for direct testing for each smear‐grade (smear‐negative, scanty, 1+, 2+, 3+) were 76/180 (42.2%), 35/91 (38.5%), 47/213 (22.1%), 29/200 (14.5%), and 70/364 (19.2%), respectively.

#### B. Investigations of heterogeneity {#CD010705-sec4-0009}

##### 1. Indirect testing {#CD010705-sec5-0009}

###### (a) Individual drugs within the drug class {#CD010705-sec6-0012}

We present accuracy estimates for MTBDR*sl* version 1.0 by indirect testing for detection of resistance to amikacin, kanamycin, and capreomycin in [Table 9](#CD010705-tbl-0009){ref-type="table"} and [Figure 9](#CD010705-fig-0009){ref-type="fig"}.Figure 9Forest plots of MTBDR*sl* sensitivity and specificity for the detection of resistance to amikacin, kanamycin, and capreomycin, the test performed indirectly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

For detection of amikacin resistance by indirect testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 75% to 100% and specificity estimates ranged from 95% to 100%. The pooled sensitivity and specificity (95% CI) were 84.9% (79.2% to 89.1%) and 99.1% (97.6% to 99.6%), (11 studies, 1301 participants).

For detection of kanamycin resistance by indirect testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 25% to 100% and specificity estimates ranged from 86% to 100%. The pooled sensitivity and specificity (95% CI) were 66.9% (44.1% to 83.8%) and 98.6% (96.1% to 99.5%), (nine studies, 1342 participants).

For detection of capreomycin resistance by indirect testing), MTBDR*sl* version 1.0 sensitivity estimates ranged from 21% to 100% and specificity estimates from 86% to 100%. The pooled sensitivity and specificity (95% CI) were 79.5% (58.3% to 91.4%) and 95.8% (93.4% to 97.3%), (10 studies, 1406 participants).

###### (b) Drug concentration used in culture‐based DST {#CD010705-sec6-0013}

[Appendix 5](#CD010705-sec2-0019){ref-type="app"} shows amikacin, kanamycin, and capreomycin drug concentrations used in culture‐based DST in relation to the WHO‐recommended critical concentrations.

Amikacin: five studies used the WHO‐recommended critical concentration of amikacin ([@CD010705-bbs2-0006]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0018]; [@CD010705-bbs2-0024]), whereas three did not ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0007]; [@CD010705-bbs2-0026]). [@CD010705-bbs2-0008] and [@CD010705-bbs2-0027], which each used two types of culture media, used the WHO‐recommended concentration for one culture type and a non‐recommended concentration for the other type. [@CD010705-bbs2-0009] also used two types of culture media and used the WHO‐recommended concentration for one culture type and for the other culture type, no recommended concentration exists. Between studies that used and did not use the WHO‐recommended critical concentration for amikacin, there was evidence of a statistically significant difference in specificity (P value \< 0.001), but not sensitivity (P value = 0.063).

Kanamycin: two studies used the WHO‐recommended critical concentration of kanamycin ([@CD010705-bbs2-0007]; [@CD010705-bbs2-0009] for both types of culture media), whereas seven did not ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0011]; [@CD010705-bbs2-0014]; [@CD010705-bbs2-0017]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0020]).

Capreomycin: four studies used the WHO‐recommended critical concentration of capreomycin ([@CD010705-bbs2-0008] for both culture types; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0027] for both culture types), and three did not ([@CD010705-bbs2-0003]; [@CD010705-bbs2-0020]; [@CD010705-bbs2-0026]). [@CD010705-bbs2-0009] used two types of culture media and used the WHO‐recommended concentration for one culture type and for the other culture type, no recommended concentration exists. [@CD010705-bbs2-0017] used a culture type for which no recommended concentration exists and [@CD010705-bbs2-0011] did not report the critical concentration used. There was no evidence of a statistically significant difference in MTBDR*sl* version 1.0 accuracy for capreomycin resistance between studies that used and did not use the WHO‐recommended critical concentration (P values for differences in sensitivity and specificity of 0.161 and 0.625, respectively).

Comparisons between accuracy estimates for kanamycin according to critical concentration were not possible given the small number of studies.

###### (c) Type of reference standard {#CD010705-sec6-0014}

We present MTBDR*sl* version 1.0 accuracy estimates for detection of SLID resistance against different reference standards in [Table 10](#CD010705-tbl-0010){ref-type="table"} and [Appendix 8](#CD010705-sec2-0022){ref-type="app"}.

[Reference standard is sequencing]{.ul}

Using sequencing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 62% to 100% and specificity estimates ranged from 96% to 100%, (seven studies, 962 participants). We restricted the meta‐analysis to comparative studies (six studies, 873 participants). The pooled sensitivity and specificity (95% CI) were 97.0% (77.0% to 99.7%) and 99.5% (94.5% to 100.0%). There was evidence of a significantly higher sensitivity using sequencing as the reference standard compared with culture‐based DST (P value of 0.034), but not specificity (P value of 0.456).

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

Using culture and sequencing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 30% to 85% and specificity estimates ranged from 99% to 100%, (seven studies, 1491 participants). We restricted the meta‐analysis to comparative studies (six studies, 1159 participants). The pooled sensitivity and specificity (95% CI) were 61.3% (45.8% to 74.8%) and 99.9% (99.0% to 100.0%). There was no evidence of a statistically significant difference in accuracy using culture and sequencing as the reference standard compared with culture‐based DST (P values for differences in sensitivity and specificity of 0.458 and 0.203, respectively).

[Reference standard is culture‐based DST followed by sequencing of discrepant index test‐culture‐based DST results]{.ul}

Using sequencing of discrepant results, MTBDR*sl* version 1.0 sensitivity estimates ranged from 34% to 100% and specificity estimates ranged from 95% to 100%, (three studies, 619 participants). We did not determine summary estimates because there were only three studies and the sensitivity was variable.

##### 2. Direct testing {#CD010705-sec5-0010}

###### (a) Individual drugs within the drug class {#CD010705-sec6-0015}

We present MTBDR*sl* accuracy estimates for detection of resistance to amikacin, kanamycin, and capreomycin by direct testing against a phenotypic culture‐based reference standard in [Figure 10](#CD010705-fig-0010){ref-type="fig"}.Figure 10Forest plots of MTBDR*sl* sensitivity and specificity for resistance to amikacin, kanamycin, and capreomycin, the test performed directly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

For detection of amikacin resistance by direct testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 64% to 100% and specificity estimates ranged from 88% to 100%. The pooled sensitivity and specificity (95% CI) were 91.9% (71.5% to 98.1%) and 99.9% (95.2% to 100.0%), (six studies, 1491 participants). Based on all data, there was no evidence of a statistically significant difference in accuracy between indirect and direct testing for amikacin resistance (P values for differences in sensitivity of specificity 0.338 and 0.213, respectively).

For detection of kanamycin resistance by direct testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 9% to 100% and specificity estimates ranged from 90% to 100%. The pooled sensitivity and specificity (95% CI) were 78.7% (11.9% to 99.0%) and 99.7% (95% CI 93.8% to 100.0%), (five studies, 1020 participants). Based on all data, there was no evidence of a statistically significant difference in accuracy between indirect and direct testing for kanamycin resistance (P values for differences in sensitivity of specificity 0.836 and 0.445, respectively).

For detection of capreomycin resistance by direct testing, MTBDR*sl* version 1.0 sensitivity estimates ranged from 57% to 100% and specificity estimates ranged from 88% to 100%. The pooled sensitivity and specificity (95% CI) were 76.6% (61.1% to 87.3%) and 98.2% (92.5% to 99.6%), (five studies, 1027 participants). Based on all data, there was no evidence of a statistically significant difference in accuracy between indirect and direct testing for capreomycin resistance (P values for differences in sensitivity and specificity of 0.841 and 0.353, respectively).

###### (b) Drug concentration used in culture‐based {#CD010705-sec6-0016}

Amikacin: all six studies in this category used the WHO‐recommended critical concentration ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0002]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0024]).

Kanamycin: three studies used the WHO‐recommended critical concentration for kanamycin ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0025]), whereas two did not ([@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]).

Capreomycin: all five studies used the WHO‐recommended critical concentration ([@CD010705-bbs2-0001]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0025]).

Comparisons between accuracy estimates according to whether or not WHO‐recommended critical drug concentrations were used for culture‐based reference testing were not possible.

###### (c) Stratification by smear grade {#CD010705-sec6-0017}

There were limited data on MTBDR*sl* version 1.0 accuracy for individual SLID drugs by smear grade. [Figure 11](#CD010705-fig-0011){ref-type="fig"} presents the forest plots for amikacin resistance by smear grade.Figure 11Forest plots of MTBDR*sl* sensitivity and specificity for detection of amikacin resistance by smear grade, using culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

###### (d) Type of reference standard {#CD010705-sec6-0018}

[Reference standard is sequencing]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing and used sequencing as a reference standard.

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing and used both culture‐based DST and sequencing (performed on all isolates) as a reference standard.

[Reference standard is culture‐based DST followed by sequencing of discrepant index test culture‐based DST results]{.ul}

We identified two studies, both of which reported perfect sensitivity and specificity (95% CI): 100% (85% to 100%) and 100% (97% to 100%) for [@CD010705-bbs2-0001], and 100% (92% to 100%) and 100% (98% to 100%) for [@CD010705-bbs2-0002], respectively.

### III. XDR‐TB detection {#CD010705-sec3-0021}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0010}

##### 1. Indirect testing {#CD010705-sec5-0011}

Eight studies (880 participants, 173 (19.7%) confirmed cases of XDR‐TB) evaluated MTBDR*sl* version 1.0 by indirect testing for detection of XDR‐TB, ([Figure 12](#CD010705-fig-0012){ref-type="fig"}). Sensitivity estimates ranged from 20% to 100% and specificity estimates ranged from 96% to 100%. The pooled sensitivity and specificity (95% CI) were 70.9% (42.9% to 88.8%) and 98.8% (96.1% to 99.6%).Figure 12Forest plots of MTBDR*sl* sensitivity and specificity for the detection of XDR‐TB, the test performed indirectly and directly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

##### 2. Direct testing {#CD010705-sec5-0012}

Six studies (1420 participants, 143 (10.1%) confirmed cases of XDR‐TB) evaluated MTBDR*sl* version 1.0 by direct testing for detection of XDR‐TB, ([Figure 12](#CD010705-fig-0012){ref-type="fig"}). Sensitivity estimates ranged from 14% to 92% and specificity estimates ranged from 82% to 100%. The pooled sensitivity and specificity (95% CI ) were 69.4% (38.8% to 89.0%) and 99.4% (95.0% to 99.3%).

##### 3. Comparison of indirect versus direct testing {#CD010705-sec5-0013}

###### (a) Diagnostic accuracy {#CD010705-sec6-0019}

Based on analysis of all data, there was no evidence of a statistically significant difference in MTBDR*sl* version 1.0 accuracy for XDR‐TB between indirect and direct testing when using culture‐based DST as a reference standard (P values for differences in sensitivity and specificity of 0.916 and 0.387, respectively) ([Table 8](#CD010705-tbl-0008){ref-type="table"}). Direct within‐study comparisons were not possible because no studies performed MTBDR*sl* version 1.0 testing on specimens and isolates from the same patients.

###### (b) Indeterminate rates {#CD010705-sec6-0020}

For indirect testing for XDR‐TB, of the six studies that reported version 1.0 results, one (0.2%) of 554 was indeterminate (one culture DST sensitive). For direct testing on a smear‐positive specimen, of seven studies that reported indeterminate MTBDR*sl* results, 224 (13.5%) of 1665 results were indeterminate (27 culture‐DST resistant, 186 culture‐DST susceptible, and 11 of unknown phenotypic culture status). The indeterminate rates for direct testing for each smear‐grade (smear‐negative, scanty, 1+, 2+, 3+) were 81/183 (44.2%), 39/186 (21.0%), 53/225 (23.5%), 33/301 (11.0%), and 82/177 (46.3%).

#### B. Investigations of heterogeneity {#CD010705-sec4-0011}

##### 1. Indirect testing {#CD010705-sec5-0014}

###### (a) Drugs used in the culture‐based DST {#CD010705-sec6-0021}

One of the eight studies that performed indirect testing for XDR‐TB and used culture‐based DST as a reference standard used ofloxacin and kanamycin ([@CD010705-bbs2-0014]). Two studies used ofloxacin, amikacin, and capreomycin ([@CD010705-bbs2-0008]; [@CD010705-bbs2-0027]). One study used ofloxacin, amikacin, and kanamycin ([@CD010705-bbs2-0019]). One study used levofloxacin, amikacin, kanamycin, and capreomycin ([@CD010705-bbs2-0005]). One study used ofloxacin, amikacin, kanamycin, and capreomycin ([@CD010705-bbs2-0010]). One study used ofloxacin, kanamycin, and capreomycin ([@CD010705-bbs2-0011]). One study used moxifloxacin, amikacin, and ofloxacin ([@CD010705-bbs2-0026]).

As all but two studies used a different combination of drugs, we did not compare test performance according to drugs used in the culture‐based DST.

###### (b) Drug concentration used in culture‐based DST {#CD010705-sec6-0022}

Ofloxacin: two studies in this category used the WHO‐recommended critical concentration for ofloxacin ([@CD010705-bbs2-0010]; [@CD010705-bbs2-0019]), and two did not ([@CD010705-bbs2-0011]; [@CD010705-bbs2-0014]). Two studies used two different types of culture but only used the WHO‐recommended critical concentration of ofloxacin for one type of culture ([@CD010705-bbs2-0008]; [@CD010705-bbs2-0027]).

Moxifloxacin: [@CD010705-bbs2-0026] used moxifloxacin but did not use the WHO‐recommended critical concentration.

Levofloxacin: for the study that used levofloxacin ([@CD010705-bbs2-0005]), the WHO does not recommend a critical concentration for the type of culture used (Ogawa culture).

Amikacin: for the six studies that used amikacin, two used the WHO‐recommended critical concentration ([@CD010705-bbs2-0010]; [@CD010705-bbs2-0019]), one did not report the concentration used ([@CD010705-bbs2-0005]), and one used a type of culture‐based testing (Middlebrook 7H10 media) for which the WHO did not specify a recommended critical concentration ([@CD010705-bbs2-0026]). Two studies used two types of culture medium, one of which was done at a recommended concentration and the other not ([@CD010705-bbs2-0008];[@CD010705-bbs2-0027]).

Kanamycin: of the five studies that used kanamycin, four did not use the WHO‐recommended critical concentration ([@CD010705-bbs2-0010]; [@CD010705-bbs2-0011]; [@CD010705-bbs2-0014]; [@CD010705-bbs2-0019]), and one did not report the concentration used ([@CD010705-bbs2-0005]).

Capreomycin: of the seven studies that used capreomycin, four used the WHO‐recommended critical concentration ([@CD010705-bbs2-0008] for both culture types; [@CD010705-bbs2-0010]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0027] for both culture types), whereas one study did not ([@CD010705-bbs2-0026]); and two studies did not report the concentration used ([@CD010705-bbs2-0005]; [@CD010705-bbs2-0011]).

We did not compare MTBDR*sl* version 1.0 accuracy according to drug concentrations used in the culture‐based DST because there were few studies that used the same drugs and the same critical concentrations.

###### (c) Type of reference standard {#CD010705-sec6-0023}

We present MTBDR*sl* version 1.0 accuracy estimates for detection of XDR‐TB against different reference standards in [Table 10](#CD010705-tbl-0010){ref-type="table"} and [Figure 13](#CD010705-fig-0013){ref-type="fig"}.Figure 13Forest plots of MTBDR*sl* sensitivity and specificity for extensively drug‐resistant tuberculosis (XDR‐TB), the test performed indirectly against three different reference standards. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

[Reference standard is sequencing]{.ul}

For individual studies (four studies, 630 participants), MTBDR*sl* version 1.0 sensitivity estimates in all four studies were 100% and specificity estimates ranged from 95% to 100%. We restricted the meta‐analysis to comparative studies (three studies, 541 participants). Using a fixed‐effect model, the pooled sensitivity and specificity (95% CI) were 100% (94.6% to 100.0%) and 97.9% (96.3% to 98.8%).

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

We identified two studies with 435 participants. MTBDR*sl* version 1.0 sensitivity and specificity estimates (95% CI) were 56% (45% to 67%) and 99% (96% to 100%) for [@CD010705-bbs2-0011], and 71% (44% to 90%) and 99% (95% to 100%) for [@CD010705-bbs2-0019]. We did not perform a meta‐analysis.

[Reference standard is culture‐based DST followed by sequencing of discrepant index test‐culture‐based DST results]{.ul}

No studies performed indirect MTBDR*sl* version 1.0 testing for XDR‐TB and used culture‐based DST and sequencing for discrepant results as a reference standard.

##### 2. Direct testing {#CD010705-sec5-0015}

###### (a) Drugs used in the culture‐based DST {#CD010705-sec6-0024}

Two of the six studies that performed direct testing for XDR‐TB and used culture‐based DST as a reference standard used ofloxacin and amikacin ([@CD010705-bbs2-0002]; [@CD010705-bbs2-0024]). Two studies used ofloxacin, moxifloxacin, amikacin, kanamycin, and capreomycin ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]). One study used ofloxacin, amikacin, kanamycin, and capreomycin ([@CD010705-bbs2-0019]). One study used ofloxacin, kanamycin, and capreomycin ([@CD010705-bbs2-0025]).

As all but two studies used a different combination of drugs, we did not compare test performance according to drugs used in the culture‐based DST.

###### (b) Drug concentration used in culture‐based DST {#CD010705-sec6-0025}

Ofloxacin: five studies in this category used the WHO‐recommended critical concentration for ofloxacin ([@CD010705-bbs2-0002]; [@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0024]), whereas one did not ([@CD010705-bbs2-0025]).

Moxifloxacin: neither study used the WHO‐recommended critical concentration for moxifloxacin ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]).

Amikacin: four studies in this category used the WHO‐recommended critical concentration for amikacin ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0024]), whereas on study did not ([@CD010705-bbs2-0002]).

Kanamycin: two studies used the WHO‐recommended critical concentration for kanamycin ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0025]), whereas two studies did not ([@CD010705-bbs2-0016]; [@CD010705-bbs2-0019].

Capreomycin: all four studies in this category used the WHO‐recommended critical concentration for capreomycin ([@CD010705-bbs2-0004]; [@CD010705-bbs2-0016]; [@CD010705-bbs2-0019]; [@CD010705-bbs2-0025]).

We did not compare test accuracy according to drug concentrations used in the culture‐based DST because there were few studies using the same drugs and the same critical concentrations.

###### (c) Type of reference standard {#CD010705-sec6-0026}

[Reference standard is sequencing]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing for XDR‐TB and used sequencing as a reference standard.

[Reference standard is culture‐based DST and sequencing (i.e. both investigations performed on all isolates)]{.ul}

No studies performed direct MTBDR*sl* version 1.0 testing and used both culture‐based DST and sequencing (performed on all isolates) as a reference standard.

[Reference standard is culture‐based DST followed by sequencing of discrepant index test‐culture‐based DST results]{.ul}

We identified two studies that used culture‐based DST and performed sequencing only on discrepant results ([@CD010705-bbs2-0002]; [@CD010705-bbs2-0019]). These studies both reported sensitivities of 92% and specificities of 100%.

### Sensitivity analyses {#CD010705-sec3-0022}

We have presented the MTBDR*sl* version 1.0 sensitivity analyses (using culture‐based DST as the reference standard) for the FQs ([Table 11](#CD010705-tbl-0011){ref-type="table"}) and the SLIDs ([Table 12](#CD010705-tbl-0012){ref-type="table"}). The sensitivity analyses made no difference to any of the findings.Table 7Sensitivity analyses MTBDR*sl* version 1.0, fluoroquinolone resistance**Culture, indirect testingCulture, direct testingPooled sensitivity P value^1^Pooled specificity P value^1^Number of studies (participants)Pooled sensitivity (95% CI)Pooled specificity (95% CI)Number of studies (participants)Pooled sensitivity (95% CI)Pooled specificity (95% CI)All studies of fluoroquinolones**19 studies (2223)85.6% (79.2 to 90.4)98.5% (95.7 to 99.5)9 studies (1771)86.2% (74.6 to 93.0)98.6% (96.9 to 99.4)0.9320.333**Was a consecutive or random sample of patients/specimens enrolled? Yes**14 studies (1979)84.1% (75.7 to 90.0)99.0% (94.8 to 99.8)9 studies (1771)86.2% (75.2 to 92.8)98.9% (97.7 to 99.5)0.7250.506**Was a case‐control design avoided? Yes**13 studies (1389)88.9 (79.4 to 94.3)98.5% (93.4 to 99.7)8 studies (1721)85.6% (72.4 to 93.1)98.5% (96.9 to 99.3)0.6130.417**Were the index test results interpreted without knowledge of the results of the reference standard? Yes**12 studies (1796)86.1% (75.9 to 92.5)99.3% (94.4 to 99.9)7 studies (982)83.8% (68.5 to 92.5)98.1% (96.4 to 99.0)0.7680.946**Was the test applied in the manner recommended by the manufacturer? Yes**18 studies (2171)85.6% (78.6 to 90.6)98.6% (95.6 to 99.6)7 studies (982)83.8% (68.5 to 92.5)98.1% (96.4 to 99.0)0.7360.652[^11]Table 8Sensitivity analyses MTBDR*sl* version 1.0, second‐line injectable drug resistance**Culture, indirect testingCulture, direct testingPooled sensitivity P value^1^Pooled specificity P value^1^Number of studies (participants)Pooled sensitivity (95% CI)Pooled specificity (95% CI)Number of studies (participants)Pooled sensitivity (95% CI)Pooled specificity (95% CI)All studies of second‐line injectable drugs**16 studies (1921)76.5% (63.3 to 86.0)99.1% (97.3 to 99.7)8 studies (1639)87.0% (38.1 to 98.6)99.5% (93.6 to 100.0)0.5470.664**Was a consecutive or random sample of patients/specimens enrolled? Yes**11 studies (1869)77.3% (58.9 to 89.0)99.2% (96.4 to 99.8)8 studies (1639)87.0% (38.1 to 98.6)99.5% (93.6 to 100.0)0.8960.873**Was a case‐control design avoided? Yes**10 studies (1088)80.2% (57.1 to 92.4)98.6% (95.3 to 99.6)8 studies (1639)87.0% (38.1 to 98.6)99.5% (93.6 to 100.0)0.8220.889**Were the index test results interpreted without knowledge of the results of the reference standard? Yes**10 studies (1513)75.4% (57.0 to 87.7)99.0% (96.0 to 99.7)6 studies (902)96.1% (40.0 to 99.9)99.2% (82.3 to 100.0)0.4710.573**Was the test applied in the manner recommended by the manufacturer? Yes**15 studies (1869)77.2% (62.6 to 87.2)99.0% (97.1 to 99.7)6 studies (902)96.1% (40.0 to 99.9)99.2% (82.3 to 100.0)0.2280.926[^12]

### MTBDR*sl* version 2.0 {#CD010705-sec3-0023}

### I. Fluoroquinolone resistance detection {#CD010705-sec3-0024}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0012}

##### 1. Indirect testing {#CD010705-sec5-0016}

By indirect testing, MTBDR*sl* version 2.0 sensitivity and specificity (95% CI) were 84% (73% to 91%) and 100% (98% to 100%) ([@CD010705-bbs2-0023]; [Figure 14](#CD010705-fig-0014){ref-type="fig"}).Figure 14Forest plots of MTBDR*sl* version 2.0 sensitivity and specificity for the detection of resistance to the fluoroquinolones (FQs) and second‐line injectable drugs (SLIDs) and extensively drug‐resistant tuberculosis (XDR‐TB), the test performed indirectly and directly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).

##### 2. Direct testing {#CD010705-sec5-0017}

By direct testing, MTBDR*sl* version 2.0 sensitivity and specificity (95% CI) were 97% (83% to 100%) and 98% (93% to 100%) on a smear‐positive specimen and 80% (28% to 99%) and 100% (40% to 100%) on a smear‐negative specimen ([@CD010705-bbs2-0023]; [Figure 15](#CD010705-fig-0015){ref-type="fig"}).Figure 15Forest plots of MTBDR*sl* version 2.0 sensitivity and specificity for the detection of resistance to the fluoroquinolones (FQs) and second‐line injectable drugs (SLIDs) and extensively drug‐resistant tuberculosis (XDR‐TB), the test performed directly on smear‐positive and smear‐negative specimens against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line).

##### 3. Drug concentration used in culture‐based DST {#CD010705-sec5-0018}

Ofloxacin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration.

Moxifloxacin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration for low‐level moxifloxacin resistance.

Levofloxacin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration.

##### 4. Indeterminate rates {#CD010705-sec5-0019}

For both indirect and direct testing for culture‐confirmed resistance to FQs, [@CD010705-bbs2-0023] reported zero indeterminate results.

### II. SLID resistance detection {#CD010705-sec3-0025}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0013}

##### 1. Indirect testing {#CD010705-sec5-0020}

For MTBDR*sl* version 2.0 performed by indirect testing, sensitivity and specificity (95% CI) were 86% (80% to 91%) and 90% (81% to 96%) ([Figure 14](#CD010705-fig-0014){ref-type="fig"}; [@CD010705-bbs2-0023]).

##### 2. Direct testing {#CD010705-sec5-0021}

By direct testing, sensitivity and specificity (95% CI) were 89% (72% to 98%) and 90% (84% to 95%) on a smear‐positive specimen and 80% (28% to 99%) and 100% (40% to 100%) on a smear‐negative specimen ([Figure 15](#CD010705-fig-0015){ref-type="fig"}; [@CD010705-bbs2-0023]).

##### 3. Drug concentration used in culture‐based DST {#CD010705-sec5-0022}

Amikacin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration of amikacin.

Kanamycin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration of kanamycin.

Capreomycin: [@CD010705-bbs2-0023] used the WHO‐recommended critical concentration of capreomycin.

##### 4. Indeterminate rates {#CD010705-sec5-0023}

For both indirect and direct testing for culture‐confirmed resistance to SLIDs, [@CD010705-bbs2-0023] reported zero indeterminate results.

### III. XDR‐TB detection {#CD010705-sec3-0026}

#### A. Estimates of the diagnostic accuracy of MTBDR*sl* using culture‐based DST as a reference standard {#CD010705-sec4-0014}

##### 1. Indirect testing {#CD010705-sec5-0024}

For MTBDR*sl* version 2.0 performed by indirect testing, sensitivity and specificity (95% CI) were 80% (66% to 91%) and 96% (82% to 98%) ([Figure 14](#CD010705-fig-0014){ref-type="fig"}; [@CD010705-bbs2-0023]).

##### 2. Direct testing {#CD010705-sec5-0025}

By direct testing, sensitivity and specificity (95% CI) were 79% (49% to 95%) and 97% (93% to 99%) on a smear‐positive specimen and 50% (1% to 99%) and 100% (59% to 100%) on a smear‐negative specimen ([Figure 15](#CD010705-fig-0015){ref-type="fig"}; [@CD010705-bbs2-0023]).

##### 3. Indeterminate rates {#CD010705-sec5-0026}

[@CD010705-bbs2-0023] reported zero indeterminate results for both indirect and direct testing for XDR‐TB.

### Comparison of the accuracy of version 1.0 and 2.0 {#CD010705-sec3-0027}

As we identified only one study that evaluated MTBDR*sl* version 2.0, we could not compare the accuracy of MTBDR*sl* version 1.0 and 2.0.

### Other analyses {#CD010705-sec3-0028}

We did not identify any reports on intra‐reader variability. One study described inter‐reader variability and reported high concordance \> 95% ([@CD010705-bbs2-0010]).

Regarding patient outcomes, only four studies described the effect of MTBDR*sl* on time‐to‐diagnosis. [@CD010705-bbs2-0018] reported the test to have a time‐to‐diagnosis of eight hours, compared to DST using the agar proportion method (21 days) or the MGIT 960 method (eight days). [@CD010705-bbs2-0020] stated that MTBDR*sl* had a median time‐to‐diagnosis of two days, compared to 11 days for the agar proportion method. [@CD010705-bbs2-0025] noted a median time‐to‐diagnosis using MTBDR*sl* of 10 days, versus 70 to 104 days for culture‐based DST. [@CD010705-bbs2-0002] reported MTBDR*sl* to have a median turn‐around‐time of one day (after the diagnosis of first‐line resistance), whereas the median turn‐around‐time for phenotypic culture‐based DST was 31 days.

Discussion {#CD010705-sec1-0006}
==========

This updated systematic review summarizes the current literature and includes 27 studies and integrates six new studies: five new studies for MTBDR*sl* version 1.0 identified since the original Cochrane review ([@CD010705-bbs2-0101]), and one study for MTBDR*sl* version 2.0. For MTBDR*sl* version 1.0, the findings in this updated review are consistent with those reported in the previous version of the review. We have presented the average sensitivities and specificities of MTBDR*sl* version 1.0 for detection of resistance to fluoroquinolones (FQs) and second‐line injectable drugs (SLIDs) and for extensively drug‐resistant tuberculosis (XDR‐TB) in the \'Summary of findings\' tables ([Table 1](#CD010705-tbl-0001){ref-type="table"}; [Table 2](#CD010705-tbl-0002){ref-type="table"}; [Table 3](#CD010705-tbl-0003){ref-type="table"}) and [Table 8](#CD010705-tbl-0008){ref-type="table"}[Table 9](#CD010705-tbl-0009){ref-type="table"}, and [Table 10](#CD010705-tbl-0010){ref-type="table"}

We found that, when we compared MTBDR*sl* version 1.0 accuracy according to whether the test was performed directly or indirectly, the sensitivities were similar for FQ resistance and SLID resistance. When used indirectly on a culture isolate, MTBDR*sl* had higher pooled sensitivity for detection of FQ resistance (85.6%) than for detection of SLID resistance (76.5%). When used directly on a smear‐positive specimen, MTBDR*sl* had similar pooled sensitivity for FQ resistance (86.2%) and SLID resistance (87.0%); however the pooled sensitivity for SLID resistance was imprecise (95% confidence interval (CI) 38.1% to 98.8%). When SLID resistance was analysed for individual drugs, the pooled sensitivity (direct testing) was highest for amikacin (92.0%)*.* For detection of XDR‐TB the pooled sensitivity of MTBDR*sl* was 70.9% by indirect testing and 69.4% by direct testing. For detection of resistance to FQs and SLIDs and XDR‐TB by either indirect or direct testing, MTBDR*sl* pooled specificity was high (\> 98%).

We compared the accuracy of MTBDR*sl* version 1.0 against different reference standards comprised of culture‐based drug susceptibility testing (DST) (the traditional reference standard) or sequencing. We looked at MTBDR*sl* version 1.0 accuracy against each type of reference standard alone or in combination (where all specimens received both culture‐based DST and sequencing). When used indirectly on a culture isolate for detection of FQ resistance, MTBDR*sl* version 1.0 had higher pooled sensitivity against sequencing than against culture‐based DST (99.3% versus 82.4%). This suggests that MTBDR*sl *is sensitive for detecting FQ resistance caused by mutations in *gyrA* (the only gene that is targeted by MTBDR*sl* for detection of FQ resistance). However, against culture‐based DST, MTBDR*sl* sensitivity for FQ resistance was only 82.4% suggesting that just less than one in five cases may be caused by mutations outside of *gyrA*, such as in *gyrB*, a gene which is not targeted by MTBDR*sl* version 1.0. An alternative explanation is that the proportion of bacilli harbouring the mutation is below the threshold of detection by MTBDR*sl* but not below the threshold of detection of the phenotypic test.

Similarly, we found higher pooled sensitivity for SLID resistance when MTBDR*sl* version 1.0 was evaluated against sequencing rather than culture‐based DST (97.0% versus 74.6%). In this case, both sequencing and MTBDR*sl* only target the *rrs* gene for resistance to SLIDs. This approach can potentially miss mutations outside of this region that are responsible for SLID resistance. Using culture‐based DST (sensitivity 74.6%), it appears that around one in four cases of SLID‐resistant TB may be caused by mutations outside of *rrs*. The prevalence of these non‐*rrs* mutations, which can occur in regions such as *tlyA*, *eis*, and *gidB* ([@CD010705-bbs2-0068]), appears to be most pronounced for kanamycin given the reduced sensitivity (66.9%) of MTBDR*sl* for resistance to this drug compared to the other SLIDs (sensitivity of 84.9% and 79.5% for amikacin and capreomycin, respectively, MTBDR*sl* performed indirectly against culture‐based DST). The sensitivity of MTBDR*sl* for SLID resistance, and in particular kanamycin resistance, is likely to vary according to the genetic background of *M. tuberculosis* strains, where some may have a greater frequency of resistance‐causing mutations that fall outside of *rrs* and different levels of cross‐resistance within the SLIDs. As in the case of the FQs, the mutation‐harbouring bacilli may fall below the limit of detection of MTBDR*sl.*

We are aware of two systematic reviews of MTBDR*sl* ([@CD010705-bbs2-0067]; [@CD010705-bbs2-0093]). [@CD010705-bbs2-0067] (11 published studies) determined MTBDR*sl* sensitivity and specificity for resistance to second‐line anti‐TB drugs using a fixed‐effect meta‐analysis model, rather than fitting the bivariate random‐effects model currently recommended. Accuracy estimates for resistance to kanamycin and capreomycin resistance were substantially lower than the ones we found. As in our review, [@CD010705-bbs2-0093] (11 published and seven unpublished studies) used a random‐effects meta‐analysis model and arrived at similar summary estimates. Our review included additional studies not included in these previous reviews. Key questions remain regarding test accuracy and potential sources of heterogeneity, including risk of bias, type of testing (indirect versus direct testing), and reference standard (for example, culture‐based DST versus genetic sequencing). We addressed several of these questions in this review. Although we intended to investigate whether the observed test accuracy varied between studies according to HIV infection status, specimen condition (frozen versus fresh), specimen type (induced sputum or extrapulmonary specimen), the drug concentration used in culture‐based DST (studies that used the World Health Organization (WHO)‐recommended concentrations versus those that did not) or population (patients suspected of having MDR‐TB or XDR‐TB), there were unfortunately insufficient data to perform these additional analyses for each target condition. We were also unable to examine sources of heterogeneity for detection of XDR‐TB due to insufficient data. We also had limited data to investigate the influence of smear grade on accuracy estimates.

Summary of main results {#CD010705-sec2-0012}
-----------------------

The main results are presented in the \'Summary of findings\' tables.

When performed indirectly on a culture isolate, MTBDR*sl* version 1.0 sensitivity for FQ resistance was 85.6% compared with 86.2% when performed directly on a smear‐positive specimen; the specificities for indirect testing (98.5%) and direct testing (98.6%) were high.When performed indirectly, MTBDR*sl* version 1.0 sensitivity for SLID resistance was 76.5% compared with 87.0% when performed directly on a smear‐positive specimen; the specificities for indirect testing (99.1%) and direct testing (99.5%) were high.When performed indirectly, MTBDR*sl* version 1.0 sensitivity for XDR‐TB was 70.9% compared with 69.4% performed directly on a smear‐positive specimen; the specificities for indirect testing (98.8%) and direct testing (98.0%) were high.For MTBDR*sl* version 1.0, we found no evidence of a statistically significant difference in accuracy between indirect testing and direct testing on a smear‐positive specimen for FQ resistance, SLID resistance, or XDR‐TB.We had insufficient data to estimate summary diagnostic accuracy of MTBDR*sl* version 2.0 (smear‐positive or smear‐negative specimens) or compare accuracy of the two versions.

### Application of the meta‐analysis to a hypothetical cohort {#CD010705-sec3-0029}

In the \'Summary of findings\' tables we have summarized the review findings for MTBDR*sl* version 1.0 by applying the results to a hypothetical cohort of 1000 individuals with rifampicin‐resistant TB or MDR‐TB thought to have resistance to a FQ, or SLID, or both ([Table 1](#CD010705-tbl-0001){ref-type="table"}; [Table 2](#CD010705-tbl-0002){ref-type="table"}; [Table 3](#CD010705-tbl-0003){ref-type="table"}). We have presented several scenarios, based on the prevalence of drug‐resistant TB suggested by the WHO of 5%, 10%, and 15% for FQ and SLID resistance and 1%, 5%, and 10% for XDR‐TB. We chose these thresholds based on the findings from global surveillance of second‐line resistance among patients with rifampicin‐resistance TB or MDR‐TB from 75 countries ([@CD010705-bbs2-0095]). The consequences of false positive (FP) results are likely patient anxiety, morbidity from additional testing, possible delays in further diagnostic evaluation, and prolonged and unnecessary treatment with drugs that may have lower bactericidal activity than second‐line regimens and often have serious side effects. The consequences of false negative (FN) results are an increased risk of patient morbidity and mortality, and continued risk of community transmission of drug‐resistant TB.

#### MTBDR*sl* version 1.0, direct testing (smear‐positive specimen) for fluoroquinolone resistance {#CD010705-sec4-0015}

By direct testing (smear‐positive specimen), the test detected 86% of people with FQ resistance and rarely gave a positive result for people without resistance. In a population of 1000 people, where 150 have FQ resistance, MTBDR*sl* will correctly identify 129 people with FQ resistance and miss 21 people. In this same population of 1000 people, where 850 people do not have FQ resistance, the test will correctly classify 838 people as not having FQ resistance and misclassify 12 people as having resistance.

#### MTBDR*sl* version 1.0, direct testing (smear‐positive specimen) for SLID resistance {#CD010705-sec4-0016}

By direct testing (smear‐positive specimen), the test detected 87% of people with SLID resistance and rarely gave a positive result for people without resistance. In a population of 1000 people, where 150 have SLID resistance, MTBDR*sl* will correctly identify 131 people with SLID resistance and miss 19 people. In this same population of 1000 people, where 850 do not have SLID resistance, the test will correctly classify 846 people as not having SLID resistance and misclassify four people as having resistance.

#### MTBDR*sl* version 1.0, direct testing (smear‐positive specimen) for XDR‐TB {#CD010705-sec4-0017}

By direct testing (smear‐positive specimen), the test detected 69% of people with XDR‐TB and rarely gave a positive result for people without resistance. In a population of 1000 people, where 100 have XDR‐TB, MTBDR*sl* will correctly identify 69 people with XDR‐TB and miss 31 people. In this same population of 1000 people, where 900 do not have XDR‐TB, the test will correctly classify 891 people as not having SLID resistance and misclassify nine people as having resistance.

Strengths and weaknesses of the review {#CD010705-sec2-0013}
--------------------------------------

The results of this review are based on strict and careful literature searches, study inclusion, and data extraction. The strength of this review is that it allows an assessment of different methods of testing (indirect versus direct) and different reference standards.

### Completeness of evidence {#CD010705-sec3-0030}

This is a reasonably complete data set. We included any non‐English studies we found from which we could obtain accuracy data. However, we acknowledge that we may have missed some studies despite the comprehensive search.

### Accuracy of the reference standards used {#CD010705-sec3-0031}

For our primary analysis, we used culture‐based DST. This was the most frequently deployed reference standard in the included studies. Although considered to be the best reference standard for drug‐resistant TB, culture‐based DST is not 100% accurate for detection of drug resistance, in particular with respect to detection of second‐line drug resistance. We also determined MTBDR*sl* accuracy using sequencing (gene sequencing of loci known to be associated with drug resistance) and both sequencing and culture‐based DST as reference standards. Many TB experts consider sequencing to be the best available reference standard, provided it encompasses all the possible resistance‐determining regions. In addition, we determined the accuracy of MTBDR*sl* against a fourth reference standard, where sequencing was only performed as part of an analysis for culture‐DST‐MTBDR*sl* discrepant results. However, in most cases we were unable to determine summary estimates due to the small number of studies and therefore were unable to compare MTBDR*sl* accuracy estimates using this reference standard with those obtained using culture‐based DST, or sequencing, or both, as the reference standard. MTBDR*sl* accuracy was generally greater when measured against a reference standard that included genetic testing. However, such genetic testing was only limited to the genes the MTBDR*sl* targeted and did not detect mutations outside of these genes that may cause phenotypic drug resistance.

### Quality and quality of reporting of the included studies {#CD010705-sec3-0032}

We judged that greater than 50% of studies had low risk of bias for the patient selection, index test, and flow and timing domains. We judged that only three studies (11%) had low risk of bias for the reference standard domain because these studies used the WHO‐recommended critical concentrations for every drug in the culture‐based DST reference standard whereas the other studies did not. Regarding applicability, we had low concern for all QUADAS‐2 domains. In general, studies were fairly well reported, though we corresponded with almost all study authors for additional data and missing information. However, accuracy data for individual drugs and smear grades was not well reported and blinding was not reported in a minority of studies. We strongly encourage future studies to follow the recommendations in the Standards for Reporting Diagnostic Accuracy (STARD) statement to improve the quality of reporting ([@CD010705-bbs2-0063]).

### Interpretability of subgroup analyses {#CD010705-sec3-0033}

We investigated potential sources of heterogeneity in the different reference standards used and the individual drugs in the FQ and SLID drug classes. We performed statistical testing and provided P values where appropriate. Where data were sufficient, we derived accuracy estimates from comparative studies of test accuracy in which the same set of studies was used for each test evaluation. Where data from comparative accuracy studies were limited, we used all relevant data. For some subgroups (for example, people living with HIV), there were insufficient data to perform an analysis.

### Completeness and relevance of the review {#CD010705-sec3-0034}

There are now several commercially‐available tests in addition to MTBDR*sl* for detection of resistance beyond MDR‐TB. These include TB Resistance Module Fluoroquinolones/Ethambutol and TB Resistance  Module Kanamycin/Amikacin/Capreomycin/Streptomycin (Autoimmun Diagnostika GmbH (AID) Strassberg); MolecuTech REBA MTB‐FQ^®^, MolecuTech REBA MTB‐KM^®^, and MolecuTech REBA MTB‐XDR^®^ (YD diagnostics, Seoul); and NiPro LiPA FQ (NiPro Co, Osaka). Our review is the most complete analysis of the diagnostic accuracy of the MTBDR*sl* test to date.

### Unpublished data {#CD010705-sec3-0035}

We did not include unpublished data.

Applicability of findings to the review question {#CD010705-sec2-0014}
------------------------------------------------

We had low concern about the applicability of the included studies to our review question as assessed by QUADAS‐2. This review mainly evaluated MTBDR*sl* version 1.0 which has recently been replaced with version 2.0. We reasoned that with the addition of new probes targeting more resistance‐causing mutations, the sensitivity of MTBDR*sl* version 2.0 would be expected to be the same or higher than that of MTBDR*sl* version 1.0 and the specificity to remain the same or decrease slightly because of the small likelihood that at least one of the probes may misprime (resulting in an increase in false‐positive results). Therefore the findings of this review should be considered applicable to the test. However, it is important to note that this review assessed sensitivity and specificity in research settings. Although the patient characteristics and settings matched our review question in most cases, as studies were carried out under research conditions, it is possible that the accuracy of MTBDR*sl* may be lower in routine practice settings.

Authors\' conclusions {#CD010705-sec1-0007}
=====================

In people with rifampicin‐resistant or multidrug‐resistant tuberculosis, MTBDR*sl* performed on a culture isolate or smear‐positive specimen may be useful in detecting second‐line drug resistance. MTBDR*sl* performed on a smear‐positive specimen correctly classified around six in seven people as having fluoroquinolone or SLID resistance, although the sensitivity estimates for SLID resistance varied. The test rarely gave a positive result for people without drug resistance. However, when second‐line drug resistance is not detected (MTBDR*sl* result is negative), conventional DST can still be used to evaluate patients for resistance to the fluoroquinolones or SLIDs.An enhancement of MTBDR*sl* version 2.0 in comparison to version 1.0 is that, according to the manufacturer, the test may be performed on a smear‐negative specimen with high diagnostic accuracy, although we had insufficient data to investigate this.Future studies should evaluate MTBDR*sl* version 2.0 in particular on smear‐negative specimens and in different laboratory settings and populations (for example, in HIV‐positive people). Test accuracy should be determined and compared using strains from different geographical regions, as these are likely to have different frequencies of resistance‐causing mutations that fall outside of the genes targeted by MTBDR*sl* (and therefore MTBDR*sl* will likely have different sensitivities for each drug class in these strains). Such future research should include as a reference standard sequencing that targets all known resistance‐determining mutations and not just those detectable using MTBDR*sl*. Future molecular tests for FQ and SLID resistance should have more genetic targets than *gyrA*, *gyrB*, *eis*, and *rrs*. Studies are needed to determine inter‐reader variability of the test. Although we recognize that WHO‐recommended critical concentrations for individual drugs may change over time, researchers should consider incorporating these critical concentrations into their culture‐based reference standards. Studies are also needed to assess the effect of MTBDR*sl* implementation on time‐to‐treatment, patient health outcomes, and cost‐effectiveness.

Development of the systematic review was in part made possible with financial support from the United States Agency for International Development (USAID) administered by the World Health Organization (WHO) Global TB Programme and the Bill and Melinda Gates Foundation. The review authors thank Dr Jon Deeks for guidance while drafting the protocol ([@CD010705-bbs2-0100]). The editorial base of the Cochrane Infectious Diseases Group is funded by UK aid from the UK Government for the benefit of developing countries (Grant: 5242). The views expressed in this review do not necessarily reflect UK government policy. GT is supported in part by the Wellcome Trust (WT099854MA) and a South African Medical Research Council Career Development Award (GT). MR is supported in part by the Effective Health Care Research Consortium, which is funded by UKaid from the UK Government Department for International Development (DFID). We are grateful to Vittoria Lutje, Information Specialist with the Cochrane Infectious Diseases Group (CIDG), for help with the search strategy. Sarah Donegan provided statistical support to the original review. We thank Katrina Ramsey, Oregon Health & Science University, Portland, USA, for technical assistance. We thank all authors of the included studies for answering our questions and providing additional data. We thank Dr Yang Wu and Dr Tomomi Kitamura for their assistance with translations and Emma L Doughty, Warwick Medical School, for help with the glossary of genetic terms.

*Amplification*

Amplification is replication of a DNA fragment to generate copies. Both the original and the newly synthesized copies can be described as the amplicons.

*Codon*

A codon is a sequence of three DNA or RNA bases that corresponds to a specific amino acid or a signal to start or stop transcription or translation. The DNA in coding regions of the genome is read in groups of three bases (A, G, C, T).

*Conjugate and amplification bands (controls)*

The conjugate band is a control to make sure that the DNA probes immobilized on the MTBDR*sl* strip test can bind *M. tuberculosis* DNA and that this is detectable, to ensure that the test is working properly. If this is not present, we will be unsure if the results of the test are due to something going wrong with the test that prevents binding of the bands, or a real phenomenon. Hence, an MTBDR*sl* test is indeterminate if the conjugate band is missing. Similarly, the amplification band is a control to make sure that the amplification of *M. tuberculosis* DNA (which is done in order to bring target DNA sequences to a detectable level) was successful. If this band is absent, and we do not see any probes corresponding to mutations appearing, we cannot discount a failure to amplify DNA rather than the presence of a susceptible strain.

*Culture isolates*

Culture isolates refers to *M. tuberculosis* cells from a clinical specimen that have been grown. For TB diagnosis, a volume of the clinical specimen is processed and incubated under conditions that promote *M. tuberculosis* growth. The cells that are grown are referred to a culture isolate.

*Drug susceptibility testing*

Drug susceptibility tests determine whether *M. tuberculosis* cells are sensitive or resistant to antibiotics. Testing may be undertaken using phenotypic or genotypic analyses. Phenotypic testing requires growth of TB in the presence of drugs that will inhibit the growth of a sensitive organism or have no impact on growth of a resistant organism. Genotypic testing involves detecting predetermined mutations in DNA that are known to make the organism resistant to a drug. When mutations causing drug resistance are not known, genotypic DST is not useful. Genotype^®^ MTBDR*sl* is a genotypic test.

*DNA sequencing*

DNA sequencing is a process to determine the nucleotide (A, G, C, T) sequence of fragments of DNA. By comparison of DNA sequences from distinct TB isolates, variations known as mutations can be identified. Some mutations in *M. tuberculosis* are known to cause drug resistance.

*Hybridization*

Hybridization is the process of allowing two nucleotide fragments to bind together if they share DNA sequences that are complementary. Hybridisation reactions can be designed such that when one strand binds to another, the reaction may produce a detectable colour change, which is what occurs in MTBDR*sl*.

*Locus*

A locus is the position of a genetic feature in the DNA sequence, like a genetic street address. Loci are standardized between genomes by reference to a common reference genome, such as H37Rv for *M. tuberculosis.*

*Promoter region*

A promoter region is a sequence of DNA where the transcriptional machinery binds before transcribing the DNA into RNA that may then be translated into an amino acid sequence.

*Resistance‐determining region*

A region of the *M. tuberculosis* genome where mutations commonly cause resistance to a specific drug.

We have adapted these definitions from [@CD010705-bbs2-0076].

MEDLINE (PubMed) {#CD010705-sec3-0036}
================

MTBDR\*.ti/ab.Genotype MTBDR\*.ti/abor/1‐2exp Tuberculosis, Pulmonary/exp Tuberculosis, Multidrug‐Resistant/MDR‐TB.ti/abXDR‐TB.ti/abMycobacterium tuberculosis/TB.ti/abtuberculosis.ti/abor/4‐103 and 11

Embase (OVID) {#CD010705-sec3-0037}
=============

tuberculosis.mp. or lung tuberculosis/ or Mycobacterium tuberculosis/ or multidrug resistant tuberculosis/(MDR‐TB or XDR‐TB).mp.exp Mycobacterium tuberculosis/1 or 2 or 3(MTBDR\* or \"Genotype MTBDR\*\").mp4 and 5

Web of Knowledge (SCI‐expanded, Conference Proceedings science) and BIOSIS previews {#CD010705-sec3-0038}
===================================================================================

Topic=(MTBDR\*) AND Topic=(tuberculosis OR TB OR MDR‐TB OR XDR‐TB)

LILACS {#CD010705-sec3-0039}
======

(tuberculosis OR TB OR mycobacterium OR MDR‐TB OR XDR‐TB) (Words) AND (MTBDR\$) (Wor

SCOPUS {#CD010705-sec3-0040}
======

(tuberculosis OR TB OR mycobacterium OR MDR‐TB OR XDR‐TB ) (title, abstract, keywords) AND (MTBDR\*) (title, abstract, keywords)

CIDG Specialized Register {#CD010705-sec3-0041}
=========================

(tuberculosis OR TB OR mycobacterium OR MDR‐TB OR XDR‐TB) AND (MTBDR\*)

ProQuest Dissertations & Theses A&I search strategy {#CD010705-sec3-0042}
===================================================

ab(tuberculosis) AND ab((diagnostic test\* OR RDT\* OR MTBDR\*))

metaRegister of Controlled Trials (mRCT) {#CD010705-sec3-0043}
========================================

(tuberculosis OR TB OR mycobacterium OR MDR‐TB OR XDR‐TB) AND (MTBDR\*)

World Health Organization International Clinical Trials Registry Platform {#CD010705-sec3-0044}
=========================================================================

(tuberculosis OR TB OR mycobacterium OR MDR‐TB OR XDR‐TB) AND (MTBDR\*)

Domain 1: Patient selection {#CD010705-sec3-0045}
===========================

Risk of bias: could the selection of patients have introduced bias? {#CD010705-sec4-0018}
-------------------------------------------------------------------

### Signaling question 1: was a consecutive or random sample of patients enrolled? {#CD010705-sec5-0027}

We scored \'yes\' if the study enrolled a consecutive or random sample of eligible patients; \'no\' if the study selected patients by convenience; and \'unclear\' if the study did not report the manner of patient selection or was not clearly reported.

### Signaling question 2: was a case‐control design avoided? {#CD010705-sec5-0028}

We scored \'yes\' if the study enrolled only TB patients with suspected resistance to second‐line drugs, including patients with confirmed multidrug‐resistant tuberculosis (MDR‐TB); \'no\' if the study enrolled TB patients with confirmed resistance to second‐line drugs; and \'unclear\' for all other scenarios or if it was not clearly reported.

### Signaling question 3: did the study avoid inappropriate exclusions? {#CD010705-sec5-0029}

An inappropriate exclusion might occur if, after the laboratory technician runs the index and reference tests, he or she does not record the test results in the study. This might occur if there were resource constraints as one might find in practice, but we did not expect this to occur in the research studies included in this review. We scored \'yes\' for all studies.

### Applicability: are there concerns that the included patients and setting do not match the review question? {#CD010705-sec5-0030}

We judged \'low\' concern if the selected specimens matched the review question, which reflects the way the test will be used in practice. We judged \'high\' concern if the selected specimens or isolates did not represent those for whom the test will be used in practice, such as in individuals who are not suspected of having drug‐resistant TB. We judged \'unclear\' concern if we could not tell.

Domain 2: Index test {#CD010705-sec3-0046}
====================

Risk of bias: could the conduct or interpretation of the index test have introduced bias? {#CD010705-sec4-0019}
-----------------------------------------------------------------------------------------

### Signaling question 1: were the index test results interpreted without knowledge of the results of the reference standard? {#CD010705-sec5-0031}

We scored this question \'yes\' if the reader of the assay was blinded to results of reference tests. We scored \'no\' if the reader of the assay was not blinded to the results of reference tests. If the specimens were from a biobank (repository that stores biological specimens) comprised of specimens with known second‐line drug resistance and the identity of these specimens was known to the assay reader, we also answered \'no\'. We scored \'unclear\' if it was not stated in the paper or if the study authors failed to answer this question.

### Signaling question 2: if a threshold was used, was it prespecified? {#CD010705-sec5-0032}

A threshold is prespecified in all versions of MTBDR*sl*. We answered this question \'yes\' for all studies.

### Applicability: are there concerns that the index test, its conduct, or its interpretation differ from the review question? {#CD010705-sec5-0033}

Variations in test technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. We judged the study to be of \'low concern\' for applicability if the test was performed as recommended by the manufacturer. We judged the study to be of \'low concern\' for applicability if the test was performed as recommended by the manufacturer. We judged the study to be of \'high concern\' when the test was applied differently than recommended by the manufacturer, for example when the test was applied to pooled sputa, and we judged the study to be of \'unclear concern\' when we could not tell. When available, we selected the high level WHO‐recommended concentration for moxifloxacin because we felt this concentration was clinically meaningful.

Domain 3: Reference standard {#CD010705-sec3-0047}
============================

Risk of bias: could the reference standard, its conduct or its interpretation have introduced bias? {#CD010705-sec4-0020}
---------------------------------------------------------------------------------------------------

### Signaling question 1: is the reference standard likely to correctly classify the target condition? {#CD010705-sec5-0034}

Culture‐based DST is not 100% accurate for detection of drug resistance, especially resistance to second‐line drugs. However, it is the test currently endorsed by WHO when performed using WHO‐recommended critical drug concentrations (defined below [@CD010705-bbs2-0092]). Therefore, for culture‐based DST, we answered \'yes\' if study authors used WHO critical concentrations for every test evaluation, \'no\' if study authors did not use critical concentrations (or if for the culture method used, WHO‐recommended critical concentrations did not exist) in any of their test evaluations, and \'unclear\' if study authors used critical concentrations in only some evaluations and not others or the authors did not specify the critical concentrations used. We selected the WHO‐recommended high level concentration for moxifloxacin because we felt this concentration was clinically meaningful.

We used the currently‐recommended WHO critical concentrations as a benchmark for judging risk of bias ([@CD010705-bbs2-0092]). For *M. tuberculosis*, the antimicrobial susceptibility testing \'critical concentration\' is defined as "for each drug, the lowest concentration that inhibits 95% (90% for pyrazinamide) of wild‐type strains of *M. tuberculosis* that have not been exposed to the drug, but that simultaneously does not inhibit strains of *M. tuberculosis* that are considered resistant that are isolated from patients who are not responding to therapy" ([@CD010705-bbs2-0065]). However, there is a lack of consensus about this definition ([@CD010705-bbs2-0099]).

Genetic sequencing (gene sequencing of loci known to be associated with drug resistance) is considered by researchers in this field to be the best reference standard for testing for the presence of drug resistance. Although sequencing may not be performed for all regions of the TB genome associated with resistance, we consider this to be a concern about the setting in which the test is applied, rather than a concern about risk of bias.

### Signaling question 2: were the reference standard results interpreted without knowledge of the results of the index test? {#CD010705-sec5-0035}

We scored \'yes\' if the reference test provided an automated result (for example, MGIT 960 DST), blinding was explicitly stated, or it was clear that the reference test was performed at a separate laboratory, or performed by different people, or both. We scored \'no\' if the study stated that the reference standard result was interpreted with knowledge of the MTBDR*sl* assay result. We scored \'unclear\' if it was not stated in the paper or if the authors failed to answer this question.

### Applicability: are there concerns that the target condition as defined by the reference standard does not match the question? {#CD010705-sec5-0036}

We judged applicability to be of \'low concern\' for all studies because the method used (phenotypic testing with and without drugs) was appropriate.

Domain 4: Flow and timing {#CD010705-sec3-0048}
=========================

Risk of bias: could the patient flow have introduced bias? {#CD010705-sec4-0021}
----------------------------------------------------------

### Signaling question 1: was there an appropriate interval between the index test and reference standard? {#CD010705-sec5-0037}

We expected the reference standard test to be undertaken at the same time as the index test (i.e. each performed on a paired sample for most studies). However, we expected some studies to include specimens from patients who had received a reference test on an earlier sample. The sample applies to some culture isolates, whose drug susceptibility profile might have been confirmed prior to the index test being available. We answered \'yes\' if the tests were paired or were separated by a few days. We answered \'no\' if reference and index tests were not done on paired samples and were separated by several months. As patients suspected of second‐line drug resistance are often on some form of anti‐TB therapy, it is possible that variation in the microbial population of specimens collected at different time points may occur. We scored \'unclear' if it was not stated in the paper or if the authors failed to answer this question.

### Signaling question 2: did all patients receive the same reference standard? {#CD010705-sec5-0038}

Our reference standard for the primary objectives was culture‐based DST and we anticipated this reference standard to be used in all studies. We answered \'yes\' if culture‐based DST was applied to all patients or a random sample of patients, \'no\' if the reference standard was only applied to a selective group of patients, and \'unclear\' if it was not stated in the paper or if the authors failed to answer this question.

### Signaling question 3: were all patients included in the analysis? {#CD010705-sec5-0039}

We determined the answer to this question by comparing the number of participants enrolled with the number of patients included in the 2 x 2 tables. We noted if the study authors reported the number of indeterminate assay results. We scored \'yes\' if the number of participants enrolled was clearly stated and corresponded to the number presented in the analysis or if exclusions were adequately described. We scored \'no\' if there were participants missing or excluded from the analysis and there was no explanation given. We scored \'unclear\' if not enough information was given to assess whether participants were excluded from the analysis.

[Figure 16](#CD010705-fig-0016){ref-type="fig"} shows forest plots of MTBDR*sl* sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin resistance detection when performed indirectly and using culture‐based DST as a reference standard.Figure 16Forest plots of MTBDR*sl* sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin resistance, the test performed indirectly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

Table 1. Ofloxacin, levofloxacin, and moxifloxacin drug concentrations used in culture‐based drug susceptibility testing in relation to the WHO‐recommended critical concentrations {#CD010705-sec3-0049}
===================================================================================================================================================================================

**StudyReference standardConcentration used (µg/mL)^1^Used WHO‐recommended critical concentration**[@CD010705-bbs2-0001]MGIT 960Ofloxacin: 2.0YesMoxifloxacin: 0.25No[@CD010705-bbs2-0002]Middlebrook 7H11 (agar proportion)Ofloxacin: 2.0Yes[@CD010705-bbs2-0003]LJ (agar proportion)Ofloxacin: 2.0Yes[@CD010705-bbs2-0004]MGIT 960Ofloxacin: 2.0YesMoxifloxacin: 0.25No[@CD010705-bbs2-0005]OgawaLevofloxacin: 1.0For Ogawa, there are no WHO‐recommended concentrations[@CD010705-bbs2-0006]MGIT 960Ofloxacin: 2.0YesMoxifloxacin: 0.25No[@CD010705-bbs2-0007]Middlebrook 7H10 (agar proportion)Moxifloxacin: 2.0Yes[@CD010705-bbs2-0008]MGIT 960 and LJOfloxacin: 2.0 for both mediaYes for MGIT 960; no for LJ[@CD010705-bbs2-0009]MGIT 960 and Middlebrook 7H11Ofloxacin: 2.0Yes for both media[@CD010705-bbs2-0010]MGIT 960Ofloxacin: 2.0Yes[@CD010705-bbs2-0011]LJ and BacT/ALERT 3DOfloxacin: 5.0 (LJ); 50 (BacT/ALERT 3D)No for LJ; for BacT/ALERT 3D, there are no WHO‐recommended concentrations[@CD010705-bbs2-0013]MGIT 960Levofloxacin: 1.5Yes[@CD010705-bbs2-0014]LJOfloxacin: 2.0No[@CD010705-bbs2-0016]MGIT 960Ofloxacin: 2.0YesMoxifloxacin: 0.25No[@CD010705-bbs2-0017]BACTEC 460TBMoxifloxacin: 0.5For BACTEC460, there are no WHO‐recommended concentrations[@CD010705-bbs2-0018]MGIT 960Ofloxacin: 2.0Yes[@CD010705-bbs2-0019]MGIT 960Ofloxacin: 2.0Yes[@CD010705-bbs2-0020]Middlebrook 7H11Ofloxacin: 2.0Yes[@CD010705-bbs2-0021]MGIT 960 and Middlebrook 7H10 (agar dilution)Moxifloxacin: 0.5 (MGIT); 1.0 (Middlebrook 7H10)For moxifloxacin using MGIT 960, the study used the WHO‐recommended low‐level concentration[@CD010705-bbs2-0023]MGIT 960 and LJ (agar proportion)Ofloxacin: 2.0 (LJ: 4.0)YesMoxifloxacin: 0.5NoLevofloxacin: 1.5Yes[@CD010705-bbs2-0024]MGIT 960Ofloxacin: 2.0Yes[@CD010705-bbs2-0025]LJ (proportion method)Ofloxacin: 2.0No[@CD010705-bbs2-0026]Middlebrook 7H10 (agar proportion)Moxifloxacin: 1.0No[@CD010705-bbs2-0027]MGIT 960 and LJ agar proportionOfloxacin: 2.0 for both mediaYes for MGIT 960; no for LJ

Abbreviations: LJ: Löwenstein‐Jensen; MGIT: Mycobacteria Growth Indicator Tube; WHO: World Health Organization.

^1^We used the high level concentration when available for all drugs. For a discussion of critical concentrations in LJ media, see [@CD010705-bbs2-0083].

Table 2. Amikacin, kanamycin, and capreomycin drug concentrations used in culture‐based drug susceptibility testing in relation to the WHO‐recommended critical concentrations {#CD010705-sec3-0050}
==============================================================================================================================================================================

**StudyReference standardConcentration used (µg/mL)Used WHO‐recommended critical concentration**[@CD010705-bbs2-0001]MGIT 960Amikacin: 1.0YesKanamycin: 2.5YesCapreomycin: 2.5Yes[@CD010705-bbs2-0002]Middlebrook 7H11 (agar proportion)Amikacin: 4.0There are no WHO‐recommended concentrations for amikacin using Middlebrook 7H11[@CD010705-bbs2-0003]LJ (agar proportion)Amikacin: 20.0NoKanamycin: 20.0NoCapreomycin: 20.0No[@CD010705-bbs2-0004]MGIT 960Amikacin: 1.0YesKanamycin: 2.5YesCapreomycin: 2.5Yes[@CD010705-bbs2-0005]OgawaAmikacin: unknownFor Ogawa, there are no WHO‐recommended concentrationsKanamycin: unknownCapreomycin: unknown[@CD010705-bbs2-0006]MGIT 960Amikacin: 1.0Yes[@CD010705-bbs2-0007]Middlebrook 7H10 (agar proportion)Amikacin: 5.0NoKanamycin: 5.0Yes[@CD010705-bbs2-0008]MGIT 960 and LJ (agar proportion)Amikacin: 1.0 for MGIT 960 and 40.0 for LJYes for MGIT 960; no for LJCapreomycin: 2.5 for MGIT 960 and 40.0 for LJYes for both types of media[@CD010705-bbs2-0009]Middlebrook 7H11 and MGIT 960Amikacin: 1.0 for MGIT 960 and 6.0 for 7H11Yes for MGIT 960; for 7H11, there is no WHO‐recommended concentration for amikacinKanamycin: 2.5 for MGIT 960 and 6.0 for 7H11Yes for MGIT 960 and 7H11Capreomycin: 2.5 for MGIT 960 and 10.0 for 7H11Yes for MGIT 960; for 7H11, there is no WHO‐recommended concentration for capreomycin[@CD010705-bbs2-0010]MGIT 960Amikacin: 1.0YesKanamycin: 5.0NoCapreomycin: 2.5Yes[@CD010705-bbs2-0011]LJ and BacT/ALERT 3DKanamycin: 10.0NoCapreomycin: unknownFor BacT/ALERT 3D, there are no WHO‐recommended concentrations[@CD010705-bbs2-0014]LJKanamycin: 20.0No[@CD010705-bbs2-0016]MGIT 960Amikacin: 1.0YesKanamycin: 5.0NoCapreomycin: 2.5Yes[@CD010705-bbs2-0017]BACTEC 460TBKanamycin: 5.0For BACTEC 460, there are no WHO‐recommended concentrationsCapreomycin: 1.25[@CD010705-bbs2-0018]Middlebrook 7H10 and MGIT 960Amikacin: 4.0 (7H10); 1.0 (MGIT 960)Yes for both media[@CD010705-bbs2-0019]MGIT 960Amikacin: 1.0YesKanamycin: 5.0NoCapreomycin: 2.5Yes[@CD010705-bbs2-0020]Middlebrook 7H11Kanamycin: 5.0NoCapreomycin: 10.0No[@CD010705-bbs2-0021]MGIT 960 and Middlebrook 7H10 (agar dilution)Amikacin: 1.0 for MGIT and 5.0 for Middlebrook 7H10Yes for MGIT 960; no for 7H10Capreomycin: 2.5 for MGIT and 10.0 for Middlebrook 7H10Yes for MGIT 960; no for 7H10[@CD010705-bbs2-0023]MGIT 960 and LJ (agar proportion)Amikacin: 1.0 for MGIT 960 and 30.0 for LJYes for both types of mediaKanamycin: 2.5 for MGIT 960 and 30.0 for LJYes for both types of mediaCapreomycin: 2.5 for MGIT 960 and 40.0 for LJYes for both types of media[@CD010705-bbs2-0024]MGIT 960Amikacin: 1.0Yes[@CD010705-bbs2-0025]LJKanamycin: 30.0YesCapreomycin: 40.0Yes[@CD010705-bbs2-0026]Middlebrook 7H10 (agar proportion)Amikacin: 5.0NoCapreomycin: 10.0No[@CD010705-bbs2-0027]MGIT 960 and LJ agar proportionAmikacin: 1.0 for MGIT 960 and 40.0 for LJYes for MGIT 960; no for LJCapreomycin: 2.5 for MGIT 960 and 40.0 for LJYes for both types of media

Abbreviations: LJ: Löwenstein‐Jensen; MGIT: Mycobacteria Growth Indicator Tube; WHO: World Health Organization.

[Figure 17](#CD010705-fig-0017){ref-type="fig"} shows forest plots of MTBDR*sl* sensitivity and specificity for fluoroquinolone (FQ) resistance detection when performed indirectly using different reference standards.Figure 17Forest plots of MTBDR*sl* sensitivity and specificity for fluoroquinolone (FQ) resistance, the test performed indirectly against different reference standards. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

[Figure 18](#CD010705-fig-0018){ref-type="fig"} shows forest plots of MTBDR*sl* sensitivity and specificity for ofloxacin and moxifloxacin resistance detection when performed directly and using culture‐based drug susceptibility testing (DST) as a reference standard.Figure 18Forest plots of MTBDR*sl* sensitivity and specificity for ofloxacin, moxifloxacin, and levofloxacin resistance, the test performed directly against culture‐based drug susceptibility testing (DST) as a reference standard. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

[Figure 19](#CD010705-fig-0019){ref-type="fig"} shows forest plots of MTBDR*sl* sensitivity and specificity when performed indirectly for second‐line injectable drug (SLID) resistance detection and using different reference standards.Figure 19Forest plots of MTBDR*sl* sensitivity and specificity for second‐line injectable drug (SLID) resistance, the test performed indirectly against three different reference standards. TP = true positive; FP = false positive; FN = false negative; TN = true negative. Values between brackets are the 95% confidence intervals (CIs) of sensitivity and specificity. The figure shows the estimated sensitivity and specificity of the study (blue square) and its 95% CI (black horizontal line). The individual studies are ordered by decreasing sensitivity.

Presented below are all the data for all of the tests entered into the review.

TestsData tables by testTestNo. of studiesNo. of participants[1 Indirect, FQ, culture](#CD010705-fig-00101){ref-type="fig"}Test 1Indirect, FQ, culture.192223[2 Indirect, ofloxacin, culture](#CD010705-fig-00102){ref-type="fig"}Test 2Indirect, ofloxacin, culture.131927[3 Indirect, moxifloxacin, culture](#CD010705-fig-00103){ref-type="fig"}Test 3Indirect, moxifloxacin, culture.6419[4 Indirect, levofloxacin, culture](#CD010705-fig-00104){ref-type="fig"}Test 4Indirect, levofloxacin, culture.2169[5 Indirect, ofloxacin, WHO critical concentration used](#CD010705-fig-00105){ref-type="fig"}Test 5Indirect, ofloxacin, WHO critical concentration used.81427[6 Indirect, ofloxacin, WHO critical concentration not used](#CD010705-fig-00106){ref-type="fig"}Test 6Indirect, ofloxacin, WHO critical concentration not used.4481[7 Indirect, SLID, culture](#CD010705-fig-00107){ref-type="fig"}Test 7Indirect, SLID, culture.161921[8 Indirect, amikacin, culture](#CD010705-fig-00108){ref-type="fig"}Test 8Indirect, amikacin, culture.111301[9 Indirect, kanamycin, culture](#CD010705-fig-00109){ref-type="fig"}Test 9Indirect, kanamycin, culture.91342[10 Indirect, capreomycin, culture](#CD010705-fig-00110){ref-type="fig"}Test 10Indirect, capreomycin, culture.101406[11 Indirect, amikacin, WHO critical concentration used](#CD010705-fig-00111){ref-type="fig"}Test 11Indirect, amikacin, WHO critical concentration used.4706[12 Indirect, capreomycin, WHO critical concentration used](#CD010705-fig-00112){ref-type="fig"}Test 12Indirect, capreomycin, WHO critical concentration used.4473[13 Indirect, amikacin, WHO critical concentration not used](#CD010705-fig-00113){ref-type="fig"}Test 13Indirect, amikacin, WHO critical concentration not used.7595[14 Indirect, capreomycin, WHO critical concentration not used](#CD010705-fig-00114){ref-type="fig"}Test 14Indirect, capreomycin, WHO critical concentration not used.6933[15 Indirect, XDR, culture](#CD010705-fig-00115){ref-type="fig"}Test 15Indirect, XDR, culture.8880[16 Indirect, FQ, sequencing](#CD010705-fig-00116){ref-type="fig"}Test 16Indirect, FQ, sequencing.7974[17 Indirect, SLID, sequencing](#CD010705-fig-00117){ref-type="fig"}Test 17Indirect, SLID, sequencing.7962[18 Indirect, XDR, sequencing](#CD010705-fig-00118){ref-type="fig"}Test 18Indirect, XDR, sequencing.4630[19 Indirect, FQ, sequencing and culture](#CD010705-fig-00119){ref-type="fig"}Test 19Indirect, FQ, sequencing and culture.71211[20 Indirect, SLID, sequencing and culture](#CD010705-fig-00120){ref-type="fig"}Test 20Indirect, SLID, sequencing and culture.71491[21 Indirect, XDR, sequencing and culture](#CD010705-fig-00121){ref-type="fig"}Test 21Indirect, XDR, sequencing and culture.2435[22 Indirect, FQ, culture followed by sequencing of discrepants](#CD010705-fig-00122){ref-type="fig"}Test 22Indirect, FQ, culture followed by sequencing of discrepants.3427[23 Indirect, SLID, culture followed by sequencing of discrepants](#CD010705-fig-00123){ref-type="fig"}Test 23Indirect, SLID, culture followed by sequencing of discrepants.3619[24 Direct, FQ, culture](#CD010705-fig-00124){ref-type="fig"}Test 24Direct, FQ, culture.91771[25 Direct, ofloxacin, culture](#CD010705-fig-00125){ref-type="fig"}Test 25Direct, ofloxacin, culture.71667[26 Direct, moxifloxacin, culture](#CD010705-fig-00126){ref-type="fig"}Test 26Direct, moxifloxacin, culture.2821[27 Ofloxacin, smear positive](#CD010705-fig-00127){ref-type="fig"}Test 27Ofloxacin, smear positive.4963[28 Ofloxacin, smear negative](#CD010705-fig-00128){ref-type="fig"}Test 28Ofloxacin, smear negative.2120[29 Ofloxacin, smear grade = scanty](#CD010705-fig-00129){ref-type="fig"}Test 29Ofloxacin, smear grade = scanty.265[30 Ofloxacin, smear grade = 1+](#CD010705-fig-00130){ref-type="fig"}Test 30Ofloxacin, smear grade = 1+.4241[31 Ofloxacin, smear grade ≥ 2+](#CD010705-fig-00131){ref-type="fig"}Test 31Ofloxacin, smear grade ≥ 2+.4647[32 Moxifloxacin, smear positive](#CD010705-fig-00132){ref-type="fig"}Test 32Moxifloxacin, smear positive.2821[33 Moxifloxacin, smear negative](#CD010705-fig-00133){ref-type="fig"}Test 33Moxifloxacin, smear negative.191[34 Moxifloxacin, smear grade = scanty](#CD010705-fig-00134){ref-type="fig"}Test 34Moxifloxacin, smear grade = scanty.151[35 Moxifloxacin, smear grade = 1+](#CD010705-fig-00135){ref-type="fig"}Test 35Moxifloxacin, smear grade = 1+.2197[36 Moxifloxacin, smear grade ≥ 2+](#CD010705-fig-00136){ref-type="fig"}Test 36Moxifloxacin, smear grade ≥ 2+.2593[37 Direct, SLID, culture](#CD010705-fig-00137){ref-type="fig"}Test 37Direct, SLID, culture.81639[38 Direct, amikacin, culture](#CD010705-fig-00138){ref-type="fig"}Test 38Direct, amikacin, culture.61491[39 Direct, kanamycin, culture](#CD010705-fig-00139){ref-type="fig"}Test 39Direct, kanamycin, culture.51020[40 Direct, capreomycin, culture](#CD010705-fig-00140){ref-type="fig"}Test 40Direct, capreomycin, culture.51027[41 Amikacin, smear positive](#CD010705-fig-00141){ref-type="fig"}Test 41Amikacin, smear positive.4809[42 Amikacin, smear negative](#CD010705-fig-00142){ref-type="fig"}Test 42Amikacin, smear negative.2104[43 Amikacin, smear grade = scanty](#CD010705-fig-00143){ref-type="fig"}Test 43Amikacin, smear grade = scanty.357[44 Amikacin, smear grade= 1+](#CD010705-fig-00144){ref-type="fig"}Test 44Amikacin, smear grade= 1+.4222[45 Amikacin, smear grade ≥ 2+](#CD010705-fig-00145){ref-type="fig"}Test 45Amikacin, smear grade ≥ 2+.4602[46 Kananycin, smear positive](#CD010705-fig-00146){ref-type="fig"}Test 46Kananycin, smear positive.3806[47 Kanamycin, smear negative](#CD010705-fig-00147){ref-type="fig"}Test 47Kanamycin, smear negative.173[48 Kanamycin, smear grade = scanty](#CD010705-fig-00148){ref-type="fig"}Test 48Kanamycin, smear grade = scanty.243[49 Kanamycin, smear grade = +1](#CD010705-fig-00149){ref-type="fig"}Test 49Kanamycin, smear grade = +1.3193[50 Kanamycin, smear grade ≥ 2+](#CD010705-fig-00150){ref-type="fig"}Test 50Kanamycin, smear grade ≥ 2+.3564[51 Capreomycin, smear positive](#CD010705-fig-00151){ref-type="fig"}Test 51Capreomycin, smear positive.3806[52 Capreomycin, smear negative](#CD010705-fig-00152){ref-type="fig"}Test 52Capreomycin, smear negative.173[53 Capreomycin, smear grade = 1+](#CD010705-fig-00153){ref-type="fig"}Test 53Capreomycin, smear grade = 1+.3193[54 Capreomycin, smear grade = scanty](#CD010705-fig-00154){ref-type="fig"}Test 54Capreomycin, smear grade = scanty.243[55 Capreomycin, smear grade ≥ 2+](#CD010705-fig-00155){ref-type="fig"}Test 55Capreomycin, smear grade ≥ 2+.3564[56 Direct, XDR, culture](#CD010705-fig-00156){ref-type="fig"}Test 56Direct, XDR, culture.61420[57 Direct, FQ, culture followed by sequencing of discrepants](#CD010705-fig-00157){ref-type="fig"}Test 57Direct, FQ, culture followed by sequencing of discrepants.2685[58 Direct, SLID, culture followed by sequencing of discrepants](#CD010705-fig-00158){ref-type="fig"}Test 58Direct, SLID, culture followed by sequencing of discrepants.2666[59 Direct, XDR, culture followed by sequencing of discrepants](#CD010705-fig-00159){ref-type="fig"}Test 59Direct, XDR, culture followed by sequencing of discrepants.2570[60 V2, Indirect, FQ, culture](#CD010705-fig-00160){ref-type="fig"}Test 60V2, Indirect, FQ, culture.1228[61 V2, Direct, FQ, smear positive](#CD010705-fig-00161){ref-type="fig"}Test 61V2, Direct, FQ, smear positive.1155[62 V2, Direct, FQ, smear negative](#CD010705-fig-00162){ref-type="fig"}Test 62V2, Direct, FQ, smear negative.19[63 V2, Indirect, ofloxacin, culture](#CD010705-fig-00163){ref-type="fig"}Test 63V2, Indirect, ofloxacin, culture.1226[64 V2, Indirect, moxifloxacin, culture](#CD010705-fig-00164){ref-type="fig"}Test 64V2, Indirect, moxifloxacin, culture.197[65 V2, Indirect, SLID, culture](#CD010705-fig-00165){ref-type="fig"}Test 65V2, Indirect, SLID, culture.1228[66 V2, Direct, SLID, smear positive](#CD010705-fig-00166){ref-type="fig"}Test 66V2, Direct, SLID, smear positive.1164[67 V2, Direct, SLID, smear negative](#CD010705-fig-00167){ref-type="fig"}Test 67V2, Direct, SLID, smear negative.19[68 V2, Indirect, amikacin, culture](#CD010705-fig-00168){ref-type="fig"}Test 68V2, Indirect, amikacin, culture.1226[69 V2, Indirect, kanamycin, culture](#CD010705-fig-00169){ref-type="fig"}Test 69V2, Indirect, kanamycin, culture.1224[70 V2, Indirect, capreomycin, culture](#CD010705-fig-00170){ref-type="fig"}Test 70V2, Indirect, capreomycin, culture.1218[71 V2, Ofloxacin, smear positive](#CD010705-fig-00171){ref-type="fig"}Test 71V2, Ofloxacin, smear positive.1153[72 V2, Ofloxacin, smear negative](#CD010705-fig-00172){ref-type="fig"}Test 72V2, Ofloxacin, smear negative.19[73 V2, Ofloxacin, smear grade = scanty](#CD010705-fig-00173){ref-type="fig"}Test 73V2, Ofloxacin, smear grade = scanty.138[74 V2, Ofloxacin, smear grade = 1+](#CD010705-fig-00174){ref-type="fig"}Test 74V2, Ofloxacin, smear grade = 1+.156[75 V2, Ofloxacin, smear grade ≥ 2+](#CD010705-fig-00175){ref-type="fig"}Test 75V2, Ofloxacin, smear grade ≥ 2+.149[76 V2, Moxifloxacin, smear positive](#CD010705-fig-00176){ref-type="fig"}Test 76V2, Moxifloxacin, smear positive.122[77 V2, Moxifloxacin, smear grade ≥ 2+](#CD010705-fig-00177){ref-type="fig"}Test 77V2, Moxifloxacin, smear grade ≥ 2+.18[78 V2, Levofloxacin, smear positive](#CD010705-fig-00178){ref-type="fig"}Test 78V2, Levofloxacin, smear positive.153[79 V2, Levofloxacin, smear grade = scanty](#CD010705-fig-00179){ref-type="fig"}Test 79V2, Levofloxacin, smear grade = scanty.125[80 V2, Levofloxacin, smear grade = 1+](#CD010705-fig-00180){ref-type="fig"}Test 80V2, Levofloxacin, smear grade = 1+.122[81 V2, Levofloxacin, smear grade ≥ 2+](#CD010705-fig-00181){ref-type="fig"}Test 81V2, Levofloxacin, smear grade ≥ 2+.16[82 V2, Amikacin, smear positive](#CD010705-fig-00182){ref-type="fig"}Test 82V2, Amikacin, smear positive.1155[83 V2, Amikacin, smear negative](#CD010705-fig-00183){ref-type="fig"}Test 83V2, Amikacin, smear negative.19[84 V2, Amikacin, smear grade = scanty](#CD010705-fig-00184){ref-type="fig"}Test 84V2, Amikacin, smear grade = scanty.140[85 V2, Amikacin, smear grade = 1+](#CD010705-fig-00185){ref-type="fig"}Test 85V2, Amikacin, smear grade = 1+.157[86 V2, Amikacin, smear grade ≥ 2+](#CD010705-fig-00186){ref-type="fig"}Test 86V2, Amikacin, smear grade ≥ 2+.149[87 V2, Kanamycin, smear positive](#CD010705-fig-00187){ref-type="fig"}Test 87V2, Kanamycin, smear positive.1155[88 V2, Kanamycin, smear negative](#CD010705-fig-00188){ref-type="fig"}Test 88V2, Kanamycin, smear negative.17[89 V2, Kanamycin, smear grade = scanty](#CD010705-fig-00189){ref-type="fig"}Test 89V2, Kanamycin, smear grade = scanty.137[90 V2, Kanamycin, smear grade = 1+](#CD010705-fig-00190){ref-type="fig"}Test 90V2, Kanamycin, smear grade = 1+.155[91 V2, Kanamycin, smear grade ≥ 2+](#CD010705-fig-00191){ref-type="fig"}Test 91V2, Kanamycin, smear grade ≥ 2+.145[92 V2, Capreomycin, smear positive](#CD010705-fig-00192){ref-type="fig"}Test 92V2, Capreomycin, smear positive.1164[93 V2, Capreomycin, smear negative](#CD010705-fig-00193){ref-type="fig"}Test 93V2, Capreomycin, smear negative.19[94 V2, Capreomycin, smear grade = scanty](#CD010705-fig-00194){ref-type="fig"}Test 94V2, Capreomycin, smear grade = scanty.140[95 V2, Capreomycin, smear grade = 1+](#CD010705-fig-00195){ref-type="fig"}Test 95V2, Capreomycin, smear grade = 1+.157[96 V2, Capreomycin, smear grade ≥ 2+](#CD010705-fig-00196){ref-type="fig"}Test 96V2, Capreomycin, smear grade ≥ 2+.149[97 V2, Indirect, XDR, culture](#CD010705-fig-00197){ref-type="fig"}Test 97V2, Indirect, XDR, culture.1228[98 V2, Direct, XDR, smear positive](#CD010705-fig-00198){ref-type="fig"}Test 98V2, Direct, XDR, smear positive.1164[99 V2, Direct, XDR, smear negative](#CD010705-fig-00199){ref-type="fig"}Test 99V2, Direct, XDR, smear negative.19

**DateEventDescription**25 July 2016New search has been performedWe updated the search and included six new studies. We updated tuberculosis (TB) surveillance data in the [Background](#CD010705-sec1-0002){ref-type="sec"}, and revised the sections of [Index tests](#CD010705-sec3-0006){ref-type="sec"}, [Target conditions](#CD010705-sec3-0007){ref-type="sec"}, and [Statistical analysis and data synthesis](#CD010705-sec3-0014){ref-type="sec"}.25 July 2016New citation required but conclusions have not changedReview updated with six new included studies.

For both the original and updated reviews, we added an additional reference standard defined as two reference tests used together: phenotypic culture‐based drug susceptibility testing (DST) and genetic sequencing of the same samples. We added the question, \"Was a case‐control design avoided?\" to the sensitivity analyses. We stated in the protocol, [@CD010705-bbs2-0100], that we would perform sensitivity analyses for each target condition, using the subset of studies that provided one result per patient. However, these studies did not provide sufficient data for such analyses. We made several revisions in the Quality Assessment of Diagnostic Accuracy Studies (QUADAS‐2) tool. After further consultation with technical experts, we changed how we assessed risk of bias with regard to the reference standard domain of QUADAS‐2. We decided to distinguish between studies that used culture‐based DST with a WHO‐recommended critical concentration in order to define resistance (answered as \'yes\' if study consistently used recommended critical concentrations), those studies which did not (answered as \'no\'), and those studies which used critical concentrations in some evaluations and not others or the authors did not specify the critical concentrations used (answered as \'unclear\'). For concerns of applicability in the reference standard, we answered \'unclear\' if sequencing was used as the reference standard and the type of sequencing did not examine the genes known to be associated with resistance (for example, *gyrB* for the FQs and *eis* for the SLIDs). For signalling question 2 in the flow and timing domain, \"Did all patients receive the same reference standard?\", we answered \'no\' when culture followed by sequencing of discrepant results was performed. We also clarified concerns about applicability for the index test. We considered studies to be of \'high concern\' when the test was applied differently than recommended by the manufacturer, for example when the test was applied to pooled sputa. We added an investigation of heterogeneity in relation to microscopy smear grade.

Characteristics of included studies \[ordered by study ID\] {#CD010705-sec2-0025}
===========================================================

Ajbani 2012**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: India.World Bank classification of country: middle.Type of lab: hospital.Type of patients: confirmed multidrug‐resistant tuberculosis (MDR‐TB) patients.Patients were smear‐positive.Index testsManufacturer involvement: yes, in design, analysis, or manuscript production.Type of testing: direct.Type of specimens: smear‐positive.Specimen treatment: NALC‐NaOH.Specimen condition: frozen.Duration of freezing: \< 1 year.Target condition and reference standard(s)Culture (liquid; MGIT 960) used for fluoroquinolone (FQ), second‐line injectable drug (SLID).FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL).SLIDs: amikacin (1 µg/mL), capreomycin (2.5 µg/mL), and kanamycin (2.5 µg/mL).Discrepant analysis: yes, with sequencing.Flow and timingUninterpretable results reported: yesComparative NotesAlso performed discrepant analysis; in this analysis, not all patients received both culture‐based drug susceptibility testing (DST) and genetic sequencing reference standards.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Barnard 2012**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: South Africa.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients, confirmed rifampicin‐monoresistant patients, confirmed isoniazid‐monoresistant patients.Patients were smear‐positive.Index testsManufacturer involvement: yes, reduced price.Type of testing: direct.Type of specimens: smear‐positive.Specimen treatment: NALC‐NaOH.Specimen condition: fresh.Tested after storage at room temperature or refrigerated within 48 hours of collection.Target condition and reference standard(s)Culture (solid; AP (agar proportion) method on 7H11) used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs: amikacin (4 µg/mL).Discrepant analysis: yes, with sequencing.Flow and timingUninterpretable results reported: yesComparative NotesReported performance on extrapulmonary tuberculosis specimens.Reported on the utility of the index test on specimens that were culture‐contaminated (and hence could not receive a phenotypic DST).Reported on time‐to‐result.Also performed discrepant analysis; in this analysis, not all patients received both culture‐based DST and genetic sequencing reference standards.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Brossier 2010a**Study characteristics**Patient samplingCase‐control design with unknown mechanism of enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: France.World Bank classification of country: high.Type of lab: reference.Type of patients: confirmed MDR‐TB patients, confirmed extensively drug resistant tuberculosis (XDR‐TB) patients, confirmed drug‐susceptible TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; agar proportion method on LJ (Löwenstein‐Jensen) and sequencing used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs: amikacin (20 µg/mL), kanamycin (20 µg/mL), capreomycin (20 µg/mL).Genes sequenced for FQ: *gyrA* and *gyrB*.Genes sequenced for SLIDs: *rrs*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?No**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?Unclear**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Catanzaro 2015**Study characteristics**Patient samplingProspective, cross‐sectional study that enrolled consecutivelyPatient characteristics and settingCountry of origin: Manila, the Philippines; Mumbai, India; Chisinau, Moldova; and Port Elizabeth, South Africa.World Bank classification of country: low‐ and middle‐income.Type of lab: unknown.Type of patients: patients failing TB therapy or possible MDR‐TB.Index testsManufacturer involvement: no.Type of testing: indirect.The test was applied to pooled sputum specimens.Target condition and reference standard(s)Culture (MGIT (Mycobacteria Growth Indicator Tube) 960).FQ drugs: ofloxacin (2 µg/mL) moxifloxacin (0.25 µg/mL).SLIDs: amikacin (1 µg/mL), kanamycin (2.5 µg/mL), capreomycin (2.5 µg/mL).Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative NotesThe test was applied to pooled sputum specimens**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearHighDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Chikamatsu 2012**Study characteristics**Patient samplingCross‐sectional design with unknown mechanism of enrolment of participants, unknown direction of data collectionPatient characteristics and settingCountry of origin: Japan.World Bank classification of country: high.Type of lab: reference.Type of patients: unknown.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; Ogawa solid culture for FQs, unclear for SLIDs) and sequencing used for FQ, SLID.FQ drugs: levofloxacin (1 µg/mL).SLIDs: amikacin (unknown concentration), kanamycin (unknown concentration), capreomycin (unknown concentration).Genes sequenced for FQ: *gyrA*.Genes sequenced for SLIDs: *rrs*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?UnclearWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**UnclearLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?NoIf a threshold was used, was it pre‐specified?Yes**HighLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Fan 2011**Study characteristics**Patient samplingCross‐sectional design with enrolment of participants by convenience, prospective data collectionPatient characteristics and settingCountry of origin: China.World Bank classification of country: middle.Type of lab: research.Type of patients: confirmed MDR‐TB patients and confirmed XDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (liquid; MGIT 960).FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL).SLIDs: amikacin (1 µg/mL).Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?NoWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**HighLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ferro 2013**Study characteristics**Patient samplingCross‐sectional design with random enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Colombia.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed drug‐susceptible TB patients, MDR‐TB patients, MDR‐TB patients with some known second‐line resistance and XDR‐TB patients.Index testsManufacturer involvement: yes, donation of test.Type of testing: indirect.Target condition and reference standard(s)Culture‐based DST (solid, 7H10).FQ drugs: moxifloxacin 2 µg/mL.SLIDS: amikacin 5 µg/mL, kanamycin 5 µg/mL.No XDR‐TB information reported.There was no discrepant analysis.Flow and timingNot all participants were accounted for in the analyses. Uninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Unclear**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Unclear**Unclear**Hillemann 2009**Study characteristics**Patient samplingCase‐control design with the consecutive enrolment of participants, prospective data collection for clinical specimens, retrospective for culture isolatesPatient characteristics and settingCountry of origin: Germany.World Bank classification of country: high.Type of lab: reference.Type of patients: confirmed XDR‐TB patients, confirmed drug‐susceptible TB patients.The specimens tested were smear positive and smear negative.Index testsManufacturer involvement: yes, donation of tests.Type of testing: direct and indirect.Type of specimens: smear‐positive.Specimen treatment: NALC‐NaOH.Specimen condition: frozen.Duration of freezing: \> 1 year.Target condition and reference standard(s)Culture (liquid and solid; MGIT 960 and LJ) and sequencing used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL for MGIT and LJ).SLIDs: amikacin 1 µg/mL for MGIT and 40.0 µg/mL for LJ; capreomycin 2.5 µg/mL for MGIT and 40.0 µg/mL for LJ.Genes sequenced for FQ: *gyrA*.Genes sequenced for SLIDs: *rrs*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?Yes**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Huang 2011**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: China.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; 7H11 and liquid: MGIT 960) and sequencing used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs (for 7H11): amikacin (6 µg/mL), kanamycin (6 µg/mL) and capreomycin (10 µg/mL).Genes sequenced for FQ: *gyrA* and *gyrB*.Genes sequenced for SLIDs: *rrs* and *eis*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Ignatyeva 2012**Study characteristics**Patient samplingCase‐control design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Estonia.World Bank classification of country: high.Type of lab: reference.Type of patients: confirmed MDR‐TB patients, confirmed XDR‐TB patients and confirmed drug‐susceptible TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (liquid; MGIT 960) used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs: amikacin (1 µg/mL), kanamycin (5 µg/mL), and capreomycin (2.5 µg/mL).Flow and timingUninterpretable results reported: yesComparative NotesOther findings: the interpretability of the Genotype® MTBDR*sl* assay was high, varying between 98.0% and 100% for the first reading and between 95.5% and 100% for the second reading (Table 3).**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?Yes**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Jin 2013**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: China.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients and confirmed XDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; LJ) and BacT/ALERT 3D and sequencing used for FQ, SLID.FQ drugs: ofloxacin (5 and 50 µg/mL).SLIDs: kanamycin (10 µg/mL), capreomycin unknown.Genes sequenced for FQ: *gyrA*.Genes sequenced for SLIDs: *rrs*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kambli 2015a**Study characteristics**Patient samplingCross‐sectional study that enrolled consecutivelyPatient characteristics and settingCountry of origin: India.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)MGIT 960\
FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL)Flow and timingUninterpretable results reported: noComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kambli 2015b**Study characteristics**Patient samplingCross‐sectional study that enrolled consecutivelyPatient characteristics and settingCountry of origin: India.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB cases.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)MGIT 960\
Levofloxacin (1.5 µg/mL)Flow and timingUninterpretable results reported: noComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kiet 2010**Study characteristics**Patient samplingCase‐control design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Vietnam.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients with FQ resistance, confirmed FQ monoresistant patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; LJ) used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs: kanamycin (20 µg/mL), not World Health Organization (WHO)‐recommended critical concentrations for LJ solid culture.Discrepant analysis: yes.Flow and timingUninterpretable results reported: yesComparative NotesAlso performed discrepant analysis; in this analysis, not all patients received both culture‐based DST and genetic sequencing reference standards.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?Yes**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?NoIf a threshold was used, was it pre‐specified?Yes**HighLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?No**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kontsevaya 2011**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: UK.World Bank classification of country: high.Type of lab: reference.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (liquid; MGIT 960) used for FQ.FQ drugs: ofloxacin (2 µg/mL), moxifloxacin (0.25 µg/mL).Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Kontsevaya 2013**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Russia.World Bank classification of country: high.Type of lab: unknown.Type of patients: confirmed MDR‐TB cases.Median age: 35.All HIV‐infected.Previous TB: 38/90.Male: 71/90.Index testsManufacturer involvement: no.Type of testing: direct.Type of specimens: smear‐positive.Specimen treatment: unknown.Specimen condition: unknown.Duration of freezing: unknown.Target condition and reference standard(s)Culture (liquid; MGIT 960) used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL) and moxifloxacin (0.25 µg/mL).SLIDs: kanamycin (5 µg/mL), amikacin (1 µg/mL), and capreomycin (2.5 µg/mL).Discrepant analysis: no.Flow and timingUninterpretable results reported: noComparative NotesOther findings: analysis of test performance stratified according to sputum smear positivity showed that the test readability for individual drugs and their drug groups ranged from 80.0% to 100.0%, with the lowest for specimens graded 1 (Table 5). Within this group of specimens, lower readability rates were observed for the AG/CP group of drugs (20.0% of tests failed), with higher readability rates for FQ and ethambutol. Similar trends were observed in specimens graded 2 and 3 (Figure 1). Total agreement between the molecular assay and phenotypic DST was the highest (84.1%) for FQs and lowest (23.5%) for the injectable drugs.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lacoma 2012**Study characteristics**Patient samplingCross‐sectional design, all samples that received the reference standard were enrolled, prospective data collectionPatient characteristics and settingCountry of origin: Spain.World Bank classification of country: high.Type of lab: hospital.Type of patients: confirmed MDR‐TB cases.Smear‐positive patients whose specimens were tested directly: 49/54.Index testsManufacturer involvement: no.Type of testing: direct and indirect.Type of specimens: smear‐positive and smear negative.Specimen treatment: NALC‐NaOH.Specimen condition: frozen.Duration of freezing: \> 1 year.Target condition and reference standard(s)Culture (liquid; BACTEC460TB) used for FQ, SLID.FQ drugs: moxifloxacin (0.5 µg/mL).SLIDs: kanamycin (5 µg/mL) and capreomycin (1.25 µg/mL).Discrepant analysis: yes (for indirect testing only).Flow and timingUninterpretable results reported: yesComparative NotesAlso performed discrepant analysis; in this analysis, not all patients received both culture‐based DST and genetic sequencing reference standards.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Lopez‐Roa 2012**Study characteristics**Patient samplingCross‐sectional design with convenience‐based enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Spain.World Bank classification of country: high.Type of lab: hospital.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid, agar proportion): 7H11 (FQ) and 7H10 (SLID).FQ drugs: ofloxacin 2 µg/mL on 7H11.SLIDs: amikacin 4 µg/mL on 7H10.Discrepant analysis: yes.Flow and timingUninterpretable results reported: yesComparative NotesFor diagnostic accuracy, MGIT 960 was used, but MTBDR*sl* data were presented (and thus extracted) using the agar proportion method in 7H10 or 7H11 as a reference standard. Other findings: the turnaround time for agar proportion, MGIT 960 and GenoType® MTBDR*sl* were, respectively, 21 days, 8 days, and 8 hours. Also performed discrepant analysis; in this analysis, not all patients received both culture‐based DST and genetic sequencing reference standards.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?NoWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**HighLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Miotto 2012**Study characteristics**Patient samplingIsolates: case‐control design with consecutive enrolment of participants, prospective data collection\
Specimens: cross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Unclear.World Bank classification of country: Unclear.Type of lab: hospital.Type of patients: confirmed MDR‐TB cases, confirmed XDR‐TB cases, confirmed MDR‐TB patients with some known second‐line resistance.Index testsManufacturer involvement: yes, donation of test.Type of testing: direct and indirect.Type of specimens: smear‐positive.Specimen treatment: NALC‐NaOH.Specimen condition: frozen.Duration of freezing: \> 1 year.Target condition and reference standard(s)Culture (liquid, MGIT 960) and sequencing used for FQ, SLID.FQ drugs: ofloxacin (2 µg/mL).SLIDs: amikacin (1.0 µg/mL), kanamycin (5.0 µg/mL), and capreomycin (2.5 µg/mL).Discrepant analysis: yes for XDR‐TB, with sequencing.Genes for FQ: *gyrA*.Genes for SLIDs: *rrs*.Flow and timingUninterpretable results reported: yesComparative NotesOther findings: negative predictive value for SLID is higher in Beijing strains.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?Yes**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Said 2012**Study characteristics**Patient samplingCross‐sectional design with consecutive‐based enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: South Africa.World Bank classification of country: middle.Type of lab: research.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: yes, financial support.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; 7H11).FQ drugs: ofloxacin (2 µg/mL).SLIDs: kanamycin (5 µg/mL) and capreomycin (10 µg/mL). Not the WHO critical concentrations for SLIDs.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative NotesOther findings: turnaround times for DST ranged from 6 to 21 days (median 11) for the agar proportion method and from 2 to 3 days (median 2) for the MTBDR*sl* assay. DST results of the MTBDR*sl* assay as compared to the agar proportion method are shown in Table 2.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Simons 2015**Study characteristics**Patient samplingRetrospective, cross‐sectional study with consecutive samplingPatient characteristics and settingCountry of origin: the Netherlands.World Bank classification of country: high.Type of lab: research.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (liquid; MGIT 960 and 7H10).FQ drugs: moxifloxacin 0.5 μg/mL for MGIT and 1 μg/mL for 7H10.SLIDs: amikacin 1.0 μg/mL for MGIT and 5 μg/mL for 7H10; and capreomycin 2.5 μg/mL for MGIT and 10 μg/mL for 7H10.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Surcouf 2011**Study characteristics**Patient samplingCross‐sectional design with consecutive‐based enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Cambodia.World Bank classification of country: low.Type of lab: unknown.Type of patients: confirmed MDR‐TB cases.Index testsManufacturer involvement: yes, donation of tests.Type of testing: indirect.Target condition and reference standard(s)Sequencing used for reference standard.FQ genes: *gyrA*.SLID genes: *rrs*.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative NotesOther findings: spoligotyping results showed that most MDR strains belonged to the Beijing family (57/101, 56%) or were Beijing like (2/101, 2%). This percentage is higher in MDR FQ‐R strains (10/14, 71%). This confirms that Beijing strains are more prone to accumulate antibiotic resistance.**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results interpreted without knowledge of the results of the index tests?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Tagliani 2015**Study characteristics**Patient samplingCross‐sectional design with consecutive‐based enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Italy, Sweden, Germany, and Moldova.World Bank classification of country: high and middle.Type of lab: supranational reference laboratory.Type of patients: confirmed MDR‐TB patients.Index testsMTBDR*sl* version 2.0Manufacturer involvement: yes, donation of tests.Type of testing: direct and indirect.Target condition and reference standard(s)Culture (liquid MGIT 960, solid: LJ proportion).FQ drugs: MGIT: ofloxacin 2 μg/mL, levofloxacin 1.5 μg/mL, moxifloxacin 0.5 μg/mL; LJ: ofloxacin 4 μg/mL.SLIDs: amikacin 1 μg/mL, kanamycin 2.5 μg/mL, and capreomycin 2.5 μg/mL; LJ: amikacin 30 μg/mL, kanamycin 30 μg/mL, and capreomycin 40 μg/mL.Discrepant sequencing on false positive samples only.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?NoWere all patients included in the analysis?Yes**Low**Tomasicchio 2016**Study characteristics**Patient samplingIsolates: case‐control design with consecutive enrolment of participants\
Specimens: cross‐sectional design with consecutive enrolment of participantsPatient characteristics and settingCountry of origin: South Africa.World Bank classification of country: middle.Type of lab: reference laboratory.Type of patients: confirmed MDR‐TB patients and patients with confirmed second‐line drug resistance.Index testsManufacturer involvement: no.Type of testing: direct and indirect.Target condition and reference standard(s)Culture (liquid MGIT 960).FQ drugs: ofloxacin 2 μg/mL.SLIDs: amikacin 1 μg/mL.Flow and timingUninterpretable results reported: yesComparative NotesA case‐control study design was used to evaluate culture isolates**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?NoDid the study avoid inappropriate exclusions?Yes**HighLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?YesWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**LowLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Tukvadze 2014**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Georgia.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: direct testing.Target condition and reference standard(s)Culture based DST, LJ.FQ: ofloxacin 2 µg/mL.SLIDS: capreomycin 40 µg/mL; kanamycin 30 µg/mL.There was no discrepant analysis.All reported XDR‐TB resistance.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?UnclearIf a threshold was used, was it pre‐specified?Yes**UnclearUnclearDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Unclear**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**van Ingen 2010**Study characteristics**Patient samplingCross‐sectional design with enrolment of participants by convenience, retrospective data collectionPatient characteristics and settingCountry of origin: NetherlandsWorld Bank classification of country: highType of lab: referenceType of patients: confirmed MDR‐TB patients, confirmed MDR‐TB patients with some known second‐line resistance.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid; 7H10).FQ drugs: moxifloxacin (1 µg/mL).SLIDs: amikacin (5 µg/mL) and capreomycin (10 µg/mL). WHO critical concentrations not used for 7H10 solid culture.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative NotesRelevant clinical information? unclear**Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?NoWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**HighHighDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?NoWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**HighLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**Zivanovic 2012**Study characteristics**Patient samplingCross‐sectional design with consecutive enrolment of participants, prospective data collectionPatient characteristics and settingCountry of origin: Serbia.World Bank classification of country: middle.Type of lab: reference.Type of patients: confirmed MDR‐TB patients.Index testsManufacturer involvement: no.Type of testing: indirect.Target condition and reference standard(s)Culture (solid and liquid; LJ and MGIT 960).FQ drugs: ofloxacin (2 µg/mL).SLIDs: amikacin (1 µg/mL for MGIT and 40 µg/mL for LJ; capreomycin 2.5 µg/mL for MGIT and 40.0 for LJ.Discrepant analysis: no.Flow and timingUninterpretable results reported: yesComparative Notes **Methodological qualityItemAuthors\' judgementRisk of biasApplicability concernsDOMAIN 1: Patient Selection**Was a consecutive or random sample of patients enrolled?YesWas a case‐control design avoided?YesDid the study avoid inappropriate exclusions?Yes**LowLowDOMAIN 2: Index Test All tests**Were the index test results interpreted without knowledge of the results of the reference standard?YesIf a threshold was used, was it pre‐specified?Yes**LowLowDOMAIN 3: Reference Standard**Is the reference standards likely to correctly classify the target condition?UnclearWere the reference standard results interpreted without knowledge of the results of the index tests?Yes**UnclearLowDOMAIN 4: Flow and Timing**Was there an appropriate interval between index test and reference standard?YesDid all patients receive the same reference standard?YesWere all patients included in the analysis?Yes**Low**[^13]

Characteristics of excluded studies \[ordered by study ID\] {#CD010705-sec2-0026}
===========================================================

StudyReason for exclusion[@CD010705-bbs2-0028]No cases with second‐line resistance.[@CD010705-bbs2-0029]Not a diagnostic accuracy study.[@CD010705-bbs2-0030]Conference abstract.[@CD010705-bbs2-0031]Technical article. Not a diagnostic accuracy study.[@CD010705-bbs2-0032]Conference abstract.[@CD010705-bbs2-0033]Technical article. Not a diagnostic accuracy study.[@CD010705-bbs2-0034]Conference abstract.[@CD010705-bbs2-0035]Technical article. No diagnostic data for fluoroquinolones (FQs), second‐line injectable drugs (SLIDs), or extensively drug‐resistant tuberculosis (XDR‐TB).[@CD010705-bbs2-0036]Conference abstract.[@CD010705-bbs2-0037]Conference abstract.[@CD010705-bbs2-0038]Not a diagnostic accuracy study.[@CD010705-bbs2-0039]Technical article. Only one case of second‐line resistance.[@CD010705-bbs2-0040]Conference abstract.[@CD010705-bbs2-0041]Conference abstract.[@CD010705-bbs2-0042]Not a diagnostic accuracy study.[@CD010705-bbs2-0043]Conference abstract.[@CD010705-bbs2-0044]Conference abstract.[@CD010705-bbs2-0045]Not a diagnostic accuracy study.[@CD010705-bbs2-0046]Conference abstract.[@CD010705-bbs2-0047]Conference abstract.[@CD010705-bbs2-0048]Data insufficient for 2 x 2 tables.[@CD010705-bbs2-0049]Test other than MTBDR*sl*.[@CD010705-bbs2-0050]Not a diagnostic accuracy study.[@CD010705-bbs2-0051]Data insufficient for 2 x 2 tables.[@CD010705-bbs2-0052]Not a diagnostic accuracy study.[@CD010705-bbs2-0053]Technical article. No information on resistance to the pre‐specified FQs and no cases susceptible to the SLIDs.[@CD010705-bbs2-0054]Technical article. No information on resistance to FQs, SLIDs, or XDR‐TB.[@CD010705-bbs2-0055]Technical article. No information on resistance to FQs, SLIDs, or XDR‐TB.[@CD010705-bbs2-0056]Conference abstract.[@CD010705-bbs2-0057]Not a diagnostic accuracy study.[@CD010705-bbs2-0058]Not a diagnostic accuracy study.[@CD010705-bbs2-0059]Conference abstract.[^14]

GT and KRS wrote the first draft of the protocol. KD and MR contributed methodological advice. RW and JP gave advice on protocol content. GT and JP reviewed the studies and extracted the accuracy data. GT, JP, and KRS assessed the methodological quality of the included studies. MR performed the statistical analyses. GT, JP, MR, KD, and KRS interpreted the findings. GT and KRS wrote the first draft of the review and prepared the \'Summary of findings\' tables. All review authors contributed to the final manuscript.

Internal sources {#CD010705-sec2-0023}
================

Liverpool School of Tropical Medicine, UK.

External sources {#CD010705-sec2-0024}
================

Medical Research Council, South Africa.Career Development Award held by GT.National Research Foundation, South Africa.Core support to KD.ACTG/IMPAACT/HVTN International Tuberculosis Speciality Laboratory, South Africa.Grant award for support to MBDepartment for International Development (DFID), UK.Grant: 5242United States Agency for International Development (USAID) administered by the World Health Organization (WHO) Global TB Programme, USA.The Bill and Melinda Gates Foundation, USA.

The review authors have no financial involvement with any organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the review apart from those disclosed.

[^1]: Editorial Group: Cochrane Infectious Diseases Group.

[^2]: Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolone; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    By indirect testing, MTBDR*sl* sensitivity and specificity (95% CI) were 85.6% (79.2% to 90.4%) and 98.5% (95.7% to 99.5%).

    \*This systematic review mainly evaluated MTBDR*sl* version 1.0, which has recently been replaced with version 2.0. We considered the findings in this review to be applicable to the current version of the test.

    ^1^Eight studies used a cross‐sectional study design and one study used a case‐control study design. ^2^We used QUADAS‐2 to assess risk of bias. All studies used consecutive sampling. In seven studies, the reader of the index test was blinded to results of the reference standard and in two studies information about blinding to the reference standard was not reported. Several studies used critical concentrations for the culture‐based DST reference standard that differed from the concentrations recommended by the WHO. This may have lowered specificity, but this was not observed. We did not downgrade. ^3^We considered indirectness (applicability) from the perspective of diagnostic accuracy and had low concern. We did not downgrade. ^4^For individual studies, sensitivity estimates ranged from 33% to 100%. One small study with the lowest sensitivity only included three FQ‐resistant patients. However, we could not explain the remaining heterogeneity by study quality or other factors. We downgraded one level for inconsistency.

[^3]: Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolone; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    By indirect testing, MTBDR*sl* sensitivity and specificity (95% CI) were 76.5% (63.3% to 86.0%) and 99.1% (97.3% to 99.7%).

    \*This systematic review mainly evaluated MTBDR*sl* version 1.0, which has recently been replaced with version 2.0. We considered the findings in this review to be applicable to the current version of the test.

    ^1^We used QUADAS‐2 to assess risk of bias. All studies used consecutive or random sampling. In six studies, the reader of the index test was blinded to results of the reference standard in two studies information about blinding to the reference standard was not reported. Fifty per cent of the studies used critical concentrations for the culture‐based DST reference standard that differed from the concentrations recommended by the WHO. We downgraded one level. ^2^We considered indirectness (applicability) from the perspective of diagnostic accuracy and had low concern. We did not downgrade. ^3^For individual studies, sensitivity estimates ranged from 9% to 100%. We thought heterogeneity could be explained in part by the use of different drugs, critical concentrations, and types of culture media in the reference standard and likely presence of *eis* mutations in patients in Eastern Europe. We did not downgrade for inconsistency and considered this in the context of other factors, in particular imprecision. ^4^The wide CI around true positives and false negatives may lead to different decisions depending on which confidence limits are assumed. We downgraded one level.

[^4]: Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolone; GRADE: Grading of Recommendations, Assessment, Development and Evaluation; SLID: second‐line injectable drug; TB: tuberculosis; WHO: World Health Organization; XDR‐TB: extensively drug‐resistant TB.

    By indirect testing, MTBDR*sl* sensitivity and specificity (95% CI) were 70.9% (42.9% to 88.7%) and 98.8% (96.1% to 99.6%).

    \*This systematic review mainly evaluated MTBDR*sl* version 1.0, which has recently been replaced with version 2.0. We considered the findings in this review to be applicable to the current version of the test.

    ^1^We used QUADAS‐2 to assess risk of bias. All studies used consecutive sampling. In four studies, the reader of the test was blinded to results of the reference standard and in two studies information about blinding was not reported. Most studies used critical concentrations for the phenotypic culture‐based DST reference standard that differed from the concentrations recommended by the WHO. We downgraded the evidence by one level. ^2^We considered indirectness (applicability) from the perspective of diagnostic accuracy and had low concern. We did not downgrade. ^3^For individual studies, sensitivity estimates ranged from 14% to 92%. We thought heterogeneity could be explained in part by the use of different drugs, critical concentrations, and types of culture media in the reference standard and likely presence of *eis* mutations in patients in Eastern Europe. We did not downgrade for inconsistency and considered this in the context of other factors, in particular imprecision. ^4^The wide CI for true positives and false negatives may lead to different decisions depending on which confidence limits are assumed. We downgraded one level.

[^5]: Abbreviations: FQ: fluoroquinolone; SLID: second‐line injectable drug.

    MTBDR*sl* reports on the presence of mutations within genes (*gyrA* and *rrs* for version 1.0 and, in addition, *gyrB* and the *eis* promoter for version 2.0), which are associated with resistance to a class of drugs. The presence of mutation(s) in these regions does not necessarily imply resistance to all the drugs within that class. Although specific mutations within these regions may be associated with different levels of resistance to each drug within these classes, the extent of this poorly understood

[^6]: Abbreviations: FQ: fluoroquinolone; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    ^1^A total of 19, 16, and 8 studies were included that evaluated MTBDR*sl* for FQ resistance, SLID resistance, and XDR‐TB, respectively, against culture‐based DST. These form the denominators to generate percentages of studies that included a particular additional reference standard.

[^7]: Abbreviations: FQ: fluoroquinolone; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    ^1^We included a total of 9, 8, and 6 studies that evaluated MTBDR*sl* for detection of FQ resistance, SLID resistance, and XDR‐TB, respectively, against culture‐based DST. These form the denominators to generate percentages of studies that included a particular additional reference standard.

[^8]: Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolone; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    The accuracy estimates were derived from non‐comparative studies of test accuracy in which different sets of studies were used. For example, for FQ resistance, the set of studies used for indirect testing differed from that used for direct testing.

    ^1^Likelihood ratio test for evidence of a significant difference between accuracy estimates.

[^9]: Abbreviations: CI: confidence interval; DST: drug susceptibility testing; FQ: fluoroquinolones; SLID: second‐line injectable drug.

    We derived the accuracy estimates from non‐comparative studies of test accuracy in which different sets of studies were used. For example, for ofloxacin resistance, the set of studies used for indirect testing differed from that used for direct testing.

    ^1^Likelihood ratio test for evidence of a significant difference between accuracy estimates. ^2^Sensitivity and specificity (95% confidence intervals (CIs)) were 80% (56 to 94) and 96% (80 to 100) for [@CD010705-bbs2-0005] and 100% (96 to 100) and 100% (88 to 100) for [@CD010705-bbs2-0013]. We did not perform a meta‐analysis.

[^10]: Abbreviations: CI: confidence interval; FQ: fluoroquinolones; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

    For detection of FQ and SLID resistance, the accuracy estimates were derived from comparative studies of test accuracy in which the same set of studies was used. For example, for FQ resistance, the set of studies using culture‐based drug susceptibility testing (DST) as a reference standard was the same as that using sequencing as a reference standard. For detection of XDR‐TB, the accuracy estimates were derived from non‐comparative studies of test accuracy in which different sets of studies were used.

    ^1^Likelihood ratio test for evidence of a significant difference between accuracy estimates. ^2^Accuracy estimates were obtained with fixed‐effect model.

[^11]: Abbreviations: CI: confidence interval.

    We derived the accuracy estimates from non‐comparative studies of test accuracy in which different sets of studies were used. ^1^Likelihood ratio test for evidence of a significant difference between accuracy estimates.

[^12]: Abbreviations: CI: confidence interval.

    We derived the accuracy estimates from non‐comparative studies of test accuracy in which different sets of studies were used. ^1^Likelihood ratio test for evidence of a significant difference between accuracy estimates.

[^13]: Abbreviations: AP: agar proportion; DST: drug susceptibility testing; FQ: fluoroquinolone; LJ: Löwenstein‐Jensen; MGIT: Mycobacteria Growth Indicator Tube; SLID: second‐line injectable drug; TB: tuberculosis; XDR‐TB: extensively drug‐resistant TB.

[^14]: Abbreviations: FQ: fluoroquinolones; SLIDs: second‐line injectable drugs; tuberculosis: TB; XDR‐TB: extensively drug‐resistant tuberculosis.
